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 The use of a ventricular assist device (VAD) is a promising option for the treatment of 
end-stage heart failure.  In many cases VADs provide not only temporary support, but contribute 
to the recovery of the native ventricle.  Many studies have reported incidences where the native 
ventricle has recovered function, leading to device explantation and eliminating the need for 
heart transplantation [1-9].  Despite strong interest in the subject for many years, the 
determinants of the recovery process are poorly understood and number of patients successfully 
weaned from chronic support remains low [10]. 
 A mathematical model was developed to gain an understanding of the complex 
mechanical interactions between a pneumatic, pulsatile VAD and the left ventricle.  The VAD 
model was verified in-vitro using a mock circulatory loop.  Over a wide range of experimental 
conditions, it correctly described observed dynamic behaviors and was accurate in predicting 
both VAD stroke volume and fill-to-empty rate within 6% error.  This validated VAD model was 
coupled to a simple, lumped parameter cardiovascular model.  The coupled model qualitatively 
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reproduced the temporal patterns of various hemodynamic variables observed in clinical data.    
A concept of VAD characteristic frequency (fc) was developed to facilitate the analysis of VAD-
ventricle synchrony.  Characteristic frequency, defined as VAD rate in the absence of ventricular 
contraction, was essentially independent of cardiovascular parameters.  For a given set of VAD 
parameters, synchrony was found to occur over a range of native heart rates.  While the lower 
bound was determined by fc alone, the upper bound was a function of various cardiovascular 
parameters (e.g., left ventricular contractility, EMAX and systemic vascular resistance, SVR).  In 
the case of synchronous behavior, the VAD and native heart have matched rates and counter-
pulse, resulting in reduced ventricular loading.  A decrease in EMAX or an increase in SVR 
increases asynchrony, resulting in frequent occurrences of co-pulsed beats (i.e., high ventricular 
loading).   
 In conclusion, we found that VAD-ventricle synchrony is determined by a complex 
interaction between VAD and cardiovascular parameters.  Our model-based analysis of VAD-
ventricle interaction may be useful for optimizing the VAD operation, characterizing native 
ventricular contractility, and better understanding of the recovery process. 
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1.0 INTRODUCTION 
In the 1960’s, when ventricular assist devices began to show promise, researchers believed the 
problems associated with heart failure would be solved within 20 years.   
        - O.H. Frazier [11] 
 
 
 Heart disease still remains the leading cause of mortality in the United States [12].  
Patients who meet the criterion of heart failure are a diverse group and have various reasons for 
elevated left ventricular (LV) filling pressure, low cardiac output, and pulmonary and peripheral 
congestion [13].  Cardiac failure affects an estimated 4.7 million Americans, with 550,000 new 
cases diagnosed annually and annual cost estimates for medical care ranging from $10 billion to 
$40 billion [12].  In most cases, the primary cause stems from the left ventricle’s inability to fill 
and empty efficiently [14].   
 The use of a ventricular assist device (VAD) is a promising option for the treatment of 
end-stage heart failure.  Many studies have been performed to examine the effects of assist 
devices on the overall performance, including effects on the circulatory system (heart, 
contractility, cardiac output, gene expression), compatibility (infection/bleeding, 
thromboemboli), and longevity [6, 15-19].  It can be concluded from these studies that in many 
cases VADs provide not only temporary support, but also contribute greatly to molecular 
remodeling and even change gene expression of the myocyte and calcium-metabolism associated 
genes.  Many studies have reported incidences where the native ventricle has recovered function 
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leading to device explantation, altogether eliminating the need for heart transplantation [1-9].  
VAD therapy is also significantly less expensive than replacement with a donor heart  [20]. 
   Despite the advantages of recovery therapy, the number of patients successfully weaned 
from mechanical support remains low [10].  One explanation is that the mechanisms of recovery 
are not fully understood.  Total ventricular unloading has been presumed to provide the optimal 
environment for recovery [21].  However, long term, total unloading of the ventricle may be 
undesirable.  It has been shown that prolonged unloading may lead to myocyte atrophy [22].  For 
this reason, partial unloading has been investigated [23].  The optimal degree of unloading is 
unknown.  Another reason for the low occurrence of recovery is that native ventricular 
performance can be difficult to ascertain in the presence of mechanical assistance.  Currently, 
“off-pump” recovery studies are the standard procedure for determining ventricular function of 
recovery candidates.  However, an “off-pump” recovery study has the inherent risk of 
temporarily removing circulatory support. Therefore only a select few patients are subjected to 
recovery studies. The optimal solution would be to have a method wherein the recoverability of 
all VAD patients could be assessed non-invasively and continuously.   
 The phasic relationship between VAD and native left ventricle contractions determines 
the degree of ventricular unloading [24]: counter-pulsations and co-pulsations reduce and 
increase ventricular load, respectively.  This phasic relationship can be monitored non-invasively 
during VAD support and may be useful in optimizing VAD operation.  In addition, we 
hypothesize that information about native ventricular contractility is embedded in the temporal 
variations of this phasic relationship.  However, better analytical tools are needed to extract this 
information from the clinical data recorded from VAD-assisted patients. 
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 In the present study, a mathematical model of the VAD-ventricle system has been 
developed.  The goal in developing this model is to gain a better understanding of the complex 
mechanical interactions between the VAD and the left ventricle.  At the University of Pittsburgh 
Medical Center (UPMC), a large percentage of recovered VAD patients received the Thoratec® 
pneumatic VAD (Thoratec Labs, Pleasanton CA).  For this reason we have chosen to focus our 
modeling efforts on this device.  The following sections describe an electric analog of the 
Thoratec® VAD that was created and verified in-vitro with a mock circulatory loop.  The VAD 
model was then coupled to a cardiovascular model.  This coupled model was used to analyze the 
behavior of the VAD-native cardiovascular system. 
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2.0 BACKGROUND 
2.1 VENTRICULAR PRESSURE-VOLUME RELATIONSHIP 
 A great deal of information can be gained about the heart by examining ventricular 
pressure-volume relationships.  This approach was first applied to the heart by Frank Otto in 
1898 [25].  Since that time, pressure-volume relationships have found many applications to aid in 
diagnosis of cardiac health. 
 Typical LV pressure and volume waveforms, as a function of time, are shown in Figure 
1A.  Ventricular pressure as a function of volume forms a loop over a complete cardiac cycle 
(Figure1B). 
 
 
Figure 1: (A) Ventricular pressure and volume waveforms of a heart.  (B) Corresponding PV Loop [26].  
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 The four phases of the cardiac cycle are easily distinguished in a pressure-volume loop.  
Ventricular filling, or diastole (a), begins with the mitral valve opening, corresponding to the 
lower left hand corner of the diagram and ends in the lower right hand corner of the loop.  At the 
end of diastole the mitral valve closes, however the pressure in the ventricle is not high enough 
to open the aortic valve.  The volume of the ventricle at the end of segment (a) is known as the 
end-diastolic volume (EDV).  The larger the EDV, the greater is the preload or stretch of 
myocardial fiber for that particular contraction.  Segment (b) is the isovolumic contraction phase.  
The ventricular muscle begins to contract, building chamber pressure, marking the beginning of 
systole.  Once the ventricular pressure exceeds aortic pressure, the aortic valve opens.  Systole 
continues into segment (c), the ventricular ejection phase. When the ventricular pressure falls 
below aortic pressure, the aortic valve closes.  The volume of the ventricle at this point is 
considered the end-systolic volume (ESV).  The final phase (d) is isovolumetric relaxation.  As 
the walls of the ventricle relax (start of diastole), pressure inside the ventricle decreases.  When 
the pressure inside the ventricle falls below that of the left atrium, the mitral valve opens and the 
cycle repeats.  
 Suga and Sagawa made valuable contributions towards the analysis of the cardiac 
contraction and pressure-volume relationship [27].  They found that the end-systolic volume and 
pressure are linearly related, independent of preload or afterload conditions.  This relationship is 
known as the end-systolic pressure-volume relationship (ESPVR).  The slope of the ESPVR is 
referred to as end-systolic elastance (EES).  EES is an index of the heart’s strength of contraction, 
or contractility. (Figure 2) 
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 Figure 2: The ESPVR, obtained by changing the loading on the ventricle [5]. 
 
 The end-diastolic pressure-volume relationship (EDPVR) is obtained by plotting the 
maximal volume during the cardiac cycle with the corresponding pressure.  The EDPVR is best 
described as a curve rather than a straight line; however the slope of the linear segment yields 
important information regarding the passive ventricular status.  A steeper EDPVR signifies that 
the ventricle, even in its relaxed state, is stiff and resistant to passive filling.  Both the ESPVR 
and EDPVR are highly valuable in clinical diagnosis of cardiac illnesses. 
2.2 HEART FAILURE & PHYSIOLOGIC COMPENSATION 
 Heart failure is a result of the ventricle’s inability to meet the body’s demand for blood 
flow [25].  This inability can arise suddenly from a heart attack or viral infection, which is 
referred to as acute heart failure. Heart failure may arise slowly over many years stemming from 
conditions such as hypertension, alcohol abuse, or hyperlipidemia.  This condition is known as 
chronic heart failure.  The heart responds to the decreased output with a variety of compensatory 
mechanisms.  Rather than improving hemodynamic performance, these mechanisms can cause 
further progression of the disease. 
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  Various types of heart failure and corresponding physiological compensations are 
illustrated using the pressure-volume construct in Figure 3 [25]. 
 
 
Figure 3: PV Loop representation of various types of heart failure [25].  (A) volume overload (B) pressure 
overload (C) restricted filling and (D) loss of contractility 
 
 In Type I heart failure, the end-systolic and end-diastolic pressure-volume relationships 
remain normal, however an abnormality such as valvular dysfunction or hypertension creates a 
greater demand on the heart.  The increase in volume (A) or pressure load (B) on the heart can be 
seen in the pressure-volume loop from the normal case (broken lines) to the diseased case (solid 
lines).  While the pumping capacity of the heart is not compromised, greater work is required to 
sustain flow.   
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 Type II heart failure is characterized by a decrease in strength of contraction, relating to a 
decrease in slope of the ESPVR.  In an attempt to maintain adequate blood flow, the circulation 
responds by increasing EDV, however with compromised contractility, the ventricle cannot 
generate adequate stroke volume.   
 Type III heart failure is characterized by a shifting of the EDPVR.  Insufficient filling 
creates a leftward shift in the EDPVR and a lower EDV.  Greater end-diastolic pressure is 
required to maintain normal stroke volume.  
 Some of the compensatory mechanisms described above can have damaging effects on 
the ventricle at the molecular level.  Increased stress and load due to compensation causes 
overexpression of neurohormones that have toxic effects on the heart muscle and blood 
vessels[28-30]. These neurohormones have been linked to ventricular remodeling, a process 
which causes a deterioration in whole ventricular function as well as individual myocytes.  The 
remodeled ventricle becomes larger, more spherical, and less capable of effective contraction 
[31].   
2.2.1 Medical Therapy for Heart Failure 
 Heart failure therapy depends greatly on the temporal status of the disease.  In early 
stages of chronic heart failure, patients are advised to undertake healthy lifestyle habits, exercise 
and diet. If symptoms worsen, a clinician will prescribe a variety of pharmaceutical therapies.  
Several types of pharmaceutical therapies exist which work to improve hemodynamic function 
[32]. 
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1. Diuretics: which can decrease circulating blood volume or preload to reduce venous 
congestion. 
 
2. Vasodilators: which can decrease afterload to improve cardiac pump function and tissue 
perfusion by dilating downstream vessels. 
 
3. Inotropic agents: which can directly increase contractility to improve cardiac output. 
 
Such drug therapies usually provide temporary deceleration or even suspension of the disease 
progression.  If symptoms of heart failure progress despite the use of drug therapies, more 
aggressive (invasive) treatment becomes necessary. 
2.2.2 Surgical Therapy for Heart Failure 
 Prior to the advent of cardiopulmonary bypass (CPB) in 1953, there were few options 
available to end stage chronic heart failure patients [33].  Prolonged bed rest was the primary 
treatment offered at the time.  Since then, several surgical options have been developed, such as 
heart transplantation, which debuted in 1967 [34].  Today heart transplantation offers the best 
chance of survival and quality of life for patients with end-stage chronic heart failure [1].  
However, the therapy is limited for a number of reasons: the need for donor organs greatly 
outnumbers the supply, complications with long-term immunosuppression and, debilitating 
effects of cardiac denervation [35]. 
 By the early 1990’s, the success of heart transplantation created a greater demand for 
donor hearts.  Unfortunately, supply of donor hearts did not meet the demands.  Because of the 
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discrepancy, waiting times for donor hearts grew in the early 90’s [11].  Mechanical circulatory 
support has provided relief to the many heart failure patients awaiting heart transplants. 
2.2.3 Mechanical Circulatory Support 
 Mechanical circulatory support has long been a challenge to engineers.  In the 1960’s 
researchers believed heart failure would be solved in 20 years [11].  The problem has since 
proved more complex.  Undoubtedly, the most famous, or infamous, historical event in the field 
of mechanical circulatory support was the Jarvik-7 implantation in 1982 [36].  The device was 
implanted with the intent of serving as “destination” therapy.  While the knowledge gained from 
the Jarvik-7 and other total artificial hearts was immeasurable to research, the clinical outcomes 
were less than desirable.  The use of a total artificial heart (TAH) as destination therapy was 
halted.  Currently, two TAH devices have been experiencing an increase in use: the CardioWest 
device (CardioWest Technologies Inc., Tucson AZ) and the AbioCor (Abiomed Inc., Danvers, 
MA).  These devices are only approved for bridge-to-transplant therapy.  
 As a result of the clinical difficulties in total heart replacement, efforts shifted to assisting 
the heart, rather than replacing it.  When originally implanted in 1963, VADs were intended to 
be used as short term support to aid patients who could not be immediately weaned from CPB.  
These devices were designed to unload the ventricle for a short period of time until normal 
function was regained.  As VAD technology improved, the devices become more useful.   
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2.2.3.1 Bridge to Transplantation 
 In 1978 a VAD was used to support a patient with severe heart disease while awaiting 
transplantation [37].  This was the first application of a VAD used as a “bridge” to 
transplantation.  Unfortunately, mortality rates on such devices were initially nearly 100% [11].  
In the late seventies and early eighties, the National Heart, Lung, and Blood Institute issued 
funding to improve the poor performance of VAD technology.  The goals were to develop a 
device for long term use (> 2 years) and to reduce the unacceptable mortality rates.  The 
initiative produced two state-of-the-art devices: the Novacor Left Ventricular Assist System 
(Novacor, Ottawa, Ontario) and the HeartMate® Left Ventricular Assist System (TCI, 
Pleasanton, CA).  Thoratec developed a second VAD, placed extracorporeally and capable or 
biventricular support.  To date, the HeartMate® has been implanted in thousands of patients with 
65% of recipients surviving to transplantation [11].  The Novacor LVAS has had similar success.  
Since their clinical introduction, these devices have increased a patient’s likelihood of surviving 
until a donor heart is found for transplant.  
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2.2.3.2 Destination Therapy 
 Destination therapy is the permanent, mechanical support of end-stage heart failure 
patients, who are ineligible for cardiac transplantation.  Recently, the HeartMate left ventricular 
assist system was approved for use as destination therapy [38].  A recent multi-center study lead 
by Rose et al. [39] concluded that improved quality of life can be achieved by implanting a 
VAD, even if no chance of transplant exists.  These events have generated new interest in the 
VAD industry as destination therapy. 
2.2.3.3 Bridge to Recovery 
 Studies have recently reported incidences where the ventricle has recovered function 
while receiving long-term VAD support.  This has allowed device explantation of the VAD in 
select cases, altogether avoiding heart transplantation.  Chronic VAD support has been linked to 
a reversal of many markers indicative of cardiac remodeling, and these observations have lead to 
the concept of “reverse remodeling” where the effects of heart failure appear to be undone as a 
result of unloading by VAD support [5, 8, 17, 40, 41].  These studies support the hypothesis that 
left ventricular assistance appears to be beneficial to LV function, and that recovery of LV 
function is possible.  Ventricular device therapy for the purpose of recovery could have 
enormous benefits on the health care industry as well, reducing the number of heart transplants 
necessary.   
 Farrar et al. concluded that recovery of the native heart is the most desirable clinical 
outcome and should be actively sought, and transplantation used only after recovery of 
 12 
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ventricular function has been ruled out [42].  This opinion is widely accepted, however many 
aspects of the recovery process remain unknown, limiting its clinical success. 
2.2.4 Recovery Studies 
 In 1995, Nakatani et al. were among the first to report on recovery of the native ventricle 
and subsequent removal of VADs in 4 of 6 heart failure patients supported for > 3 weeks [8].  
However, two of the four patients died and detailed criteria for identifying LV recovery were not 
described in their report.  Several other groups have made progress in standardizing a method to 
determine candidates for recovery [2, 43].  The Berlin Group used routine echocardiographic 
measures of LV ejection fraction and end-diastolic diameter taken with devices turned off for 4 
minutes as a guide to LV functional recovery [7].  The Columbia Presbyterian group studied 
cardiac output and peak oxygen consumption using right heart catheterization during upright 
bicycle exercise [44].  Research at UPMC has also been focused on developing a systematic 
protocol for identifying patients who might be weaned from support.  Such efforts have allowed 
clinicians to better identify ventricular recovery and have aided in lowering demand on heart 
transplantation. 
 Despite the efforts to standardize a protocol to identify recovery candidates, incidences of 
recovery remain relatively small [10].  There are several factors responsible for the limited 
success of ventricular recovery while on VAD support.  One factor is that native ventricular 
function is difficult to ascertain in the presence of VAD support.  Currently, “off-pump” 
recovery studies are the standard procedure for determining ventricular function of recovery 
candidates.  However, an “off-pump” recovery study is limited to those patients already 
displaying signs of recovery due to the inherent risk of temporarily removing circulatory support.  
Secondly, there is no standard control algorithm used which is known to optimize hemodynamic 
conditions in order to promote recovery.  If better understood, clinicians may be able to use a 
particular VAD control algorithm to train a failing ventricle towards recovery.  By training 
ventricles towards recovery, the number of potentially weanable cases can be increased, while 
better indices of recovery would improve identification of the new, larger candidate pool.  
 Efforts have been made at UPMC to develop non-invasive indices of recovery [3].  Non-
invasive indices inherently pose less risk to the subject.  By lowering risk, the pool of recovery 
candidates can be increased.  UPMC has recently reported 33% (6 of 18 patients) success rate for 
ventricular recovery of patients with VADs [3].  All six of the recovered patients were implanted 
with a Thoratec® extracorporeal pneumatic VAD.   
2.2.5 Thoratec® Pneumatic VAD 
 The Thoratec® VAD system (Thoratec Corp, Pleasanton CA.) is a pneumatically driven, 
pulsatile, extracorporeal blood pump, consisting of three major elements: blood chamber, 
cannulae and pneumatic driver.  The blood chamber consists of a hard semi-transparent casing 
and a Thorlon ® polymer blood bladder [45].  Pneumatic drive pressure is created from the Dual 
Drive Console (DDC) (Figure 4A).  The DDC is capable of providing either univentricular or 
biventricular support.   
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(A) (B)    
Figure 4: (A) Thoratec® pneumatic drive console and (B) Thoratec VAD with bi-ventricular support  [12]. 
 
 There are two control modes possible for this device, which can create very different 
hemodynamics.  In fixed mode control, pressure is supplied to the VAD at a specific frequency.  
For long-term bridge-to-transplant therapy, the most effective and reliable mode has been 
thought to be fill-to-empty control [46],wherein, the VAD ejects when full, regardless of 
ventricular state.  It maximizes blood flow; however VAD-ventricle synchrony may vary from 
beat to beat.  The VAD and ventricle are in synchrony when they contract at the same frequency.  
The significance of VAD-ventricle synchrony and its effects on LV loading and myocardial 
recovery are unknown [24],however partial loading during different periods of VAD support 
may be advantageous for myocardial recovery [23].   
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Figure 5: The VAD-ventricle system can exist in either a counter-pulsation or co-pulsation states.  When 
counter-pulsing, ventricular loading is minimal; when co-pulsing, ventricular loading is maximized [35]. 
 
 In the VAD fill-to-empty mode, the VAD-ventricle system can exist in a state of either 
co-pulsation or counter-pulsation.  Ventricular ejection coincides with VAD filling during 
counter-pulsations, minimizing ventricular loading.  In co-pulsation, ventricular and VAD 
ejection (systole) coincide; increasing ventricular loading.  Maybaum et al. suggest that, if better 
understood, VAD-ventricle synchrony could be manipulated to promote myocardial recovery.  In 
fill-to-empty control, VAD-ventricle asynchronous beats may occur regularly, randomly, or not 
at all.  The benefits of various control modes on promoting recovery are virtually unknown.  
Loading conditions on the ventricle are highly dependent on the control mode used during VAD 
support; however no standard mode exists which is known to be beneficial to recovery 
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conditions.  A mathematical model of the coupled VAD-cardiovascular system is likely to 
improve our understanding of VAD-ventricle interactions, including synchrony. 
2.2.6 Clinical Data 
 Data from two heart failure patients treated at UPMC with ventricular assist device 
(Thoratec® VAD) are shown in Figure 6.  Measurements of ventricular area were recorded using 
non-invasive echocardiographic border detection [47].  In addition, peripheral arterial pressure, 
EKG, and pneumatic VAD pressure were simultaneously recorded. 
 
Figure 6: Examples of clinical data collected at UPMC – Thoratec® VAD patients with fill-to-empty mode.   
(* indicate co-pulsations) 
 
 Patient A was a successful recovery case.  Patient B did not recover native ventricular 
function.  The asterisks (*) on the EKG data in Figure 6 indicate co-pulsation of the VAD and 
LV.  In this example, it is observed that Patient A exhibits a lower frequency of co-pulsating 
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beats than seen with Patient B.  Also, the ventricular area data for both patients shows a periodic 
dampening, possibly related to co-pulsating beats.  These phenomenons may be related to the 
underlying ventricular contractile performance.  A better understanding of the system could lead 
to indices of recovery in the presence of VAD support.  However, finding conclusive evidence 
would be difficult because of the variability in clinical data.  A mathematical model of the 
system would be useful to reconcile the variability of clinical data.   
 
2.3 CARDIOVASCULAR MODELING 
 Electric analogs are a common means of mathematically reproducing the bulk behavior 
of a fluid system, such as the cardiovascular system (CVS).  By modeling the properties of a 
fluid system representing resistance, compliance, and inertance as electric elements, accurate 
representations of cardiovascular waveforms can be simulated using electric circuit theory. 
2.3.1 Electric Analog Elements 
 Resistance occurs as a result of the frictional forces that act on a fluid traveling through a 
vessel.  These forces are represented as hydraulic resistance and are defined as the pressure drop 
through of vessel divided by the flow.  Hydraulic resistance is often a function of flow as well.  
However flow through blood vessels produce near constant resistance within physiological flow 
limits [48].  Accordingly, when modeling the CVS, linear resistors are often chosen and are 
characterized by the following constitutive relationship:  
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P(t) = R Q(t)∆ ×       (2-1) 
 
where P(t) and Q(t) are instantaneous pressure and flow, respectively and R is the hydraulic 
resistance, typically with units of mmHg×s/ml.  The simplest formulation of the resistance is 
given by the Poiseuille formula [49]:  
 
4
8×η×R=
π×r
?        (2-2) 
 
where η  is the fluid viscosity, ?  and  are the vessel length and radius, respectively.  Inertance 
is used to model inertial forces arising from the motion of the mass of blood.  Inertance is 
characterized by the following constitutive relationship:  
r
 
P(t) = L Q(t)∆ × ?        (2-3) 
 
where is the rate of change of flow, and L represents the inertance, typically with units of 
mmHg×s2/ml.  Based on the Newton’s First Law of motion, one can derive the following 
simplified expression for inertance for a cylindrical tube: 
Q(t)?
 
2
ρL = 
πr
?        (2-4) 
 
where  is the fluid density.  Due to the elastic nature of blood vessel walls, hydraulic 
compliance is a vital component to cardiovascular models.  Compliance is analogous to 
ρ
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capacitance in the electric model.  Compliance is defined by the following constitutive 
relationship: 
 
1P(t) = V(t)
C
× ∆       (2-5) 
 
where V(t) represents instantaneous volume of the vessel and C represents the hydraulic 
compliance of the vessel, typically with units of ml/mmHg.  The compliance of a cylindrical 
vessel with Young’s bulk modulus of elasticity E, and vessel wall thickness h, can be estimated 
from the following equation [50]:  
 
33πrC = 
2Eh
?        (2-6) 
2.3.2 Systemic Circulation Modeling 
 The modeling of the systemic circulation has been in existence since Frank in the late 19th 
century [51].  Since that time, a variety of approaches have been presented to model the human 
circulation.  These techniques range from reduced models with a minimal number of parameters, 
to distributed models that attempt to capture every anatomical aspect of the circulation with 
many parameters. 
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2.3.2.1 Highly Reduced Lumped Parameter Models 
 The Windkessel model was first used by Frank [51] to describe the circulation as a single 
resistance and compliance in parallel. Frank’s classic Windkessel model is depicted in Figure 
7A.  A three-element modified Windkessel model was proposed by Westerhof in 1968 [52].  The 
modified Windkessel [53] is a significant improvement over the classical Windkessel in that it 
better approximates the observed aortic input impedance spectrum (ZIN(ω)) of the systemic 
arterial circulation. 
 
 
Figure 7: (A) Classical windkessel model, R is total systemic resistance and C is arterial compliance. (B) 
Modified windkessel, Zo is characteristic impedance. 
 
 Highly reduced models, such as the modified Windkessel, provide simple and reasonably 
accurate representation of the hydraulic impedance imposed on the left ventricle.  However, 
these models ignore the distributed nature of the system arising from the anatomical features.  As 
a consequence, wave propagation and reflection phenomena are not considered in these models.  
Moreover, it is often difficult to assign calculated pressures and flows to specific anatomical 
sites; a more detailed distributed model would be required for this purpose. 
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2.3.2.2 Detailed Lumped Parameter Models 
 Distributed models do not lump system parameters.  Individual elements or segments of 
the circulation are separately modeled and assembled in an anatomically correct manner.  The 
benefits of this approach include a better representation of ZIN(ω) and availability of 
hemodynamic data at various sites in the circulation.  However, the parameter space increases 
rapidly as the model gets more complex, which adversely affects model identifiability from 
experimental data.  Figure 8 shows a diagram of a distributed human circulation model by 
Rideout [48]. 
 
 
 
Figure 8: (A) Diagram of the human CVS. (B) Corresponding distributed model of circulation [48]. 
 
 22 
 
 It can be seen that an accurate anatomical representation of the circulations is created by 
a distributed model.  Other well-known distributed models have been developed by Avolio et al. 
[54] and Noordergraaf et al. [49].   
2.3.2.3 Intermediate Hybrid Models 
 The reduced model approach remains popular because of its simplicity.  However, 
several limitations of the reduced models have been identified [55].  Detailed lumped parameter 
models, while highly accurate, are limited in the practical applications because of their large 
number of parameters.  For these reasons, intermediate models, which are both identifiable and 
accurate, have been developed.  One such intermediate modeling technique is based on the use of 
tube-like elements to simulate the distributed nature of the system and consequently, the arterial 
wave propagation and reflection phenomena [56-59].  Specifically, a single and T-tube models 
with complex terminal loads (e.g., a 3-element Windkessel) have been developed [55, 60-62].  
The term hybrid is a reflection of the fact that these types of models share properties of both 
distributed and reduced models, such as the Windkessel.  In addition to being mode accurate than 
the highly reduced models, these intermediate hybrid models have a potential for providing 
physiological relevant information about the arterial circulation.  For example, Shroff et al. [55] 
have shown that the T-tube model with complex terminal loads correctly distinguishes between 
proximal and distal arterial properties, especially the arterial compliance.  Such a distinction is 
relevant because regional changes in vascular properties can affect cardiovascular function in a 
differential manner. 
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2.3.3 Ventricular Models 
2.3.3.1 Mean Value Models 
 Early approaches to ventricular modeling related observable input(s) and output(s) of the 
ventricle [63, 64].  For example, Starling related the EDV of the ventricle (input) to cardiac 
output [63].  Guyton related mean right atrial pressure (input) to cardiac output to characterize 
the entire heart [65], while Herndon & Sagawa [66] related mean left atrial pressure and mean 
aortic pressure (inputs) to cardiac output to characterize the left ventricle in a 3-dimensional 
space.  Sarnoff introduced ventricular stroke work as the output variable and described the 
contractile state of the ventricle in terms of ventricular function curves [64, 67] by plotting mean 
atrial pressure (input) against stroke work.  Glower et al.[68] modified Sarnoff’s approach by 
replacing atrial pressure by ventricular EDV and proposed the relationship between ventricular 
EDV (input) and stroke work.  Elzinga and Westerhof related mean left ventricular pressure 
(input) to mean left ventricular outflow [69].  Mean value methods have been very useful in 
characterizing ventricular contractile function.  However, by definition, they do not provide any 
information about ventricular dynamics or pulsatile behavior. 
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2.3.3.2 Ventricular Time Varying Elastance 
 The method of time-varying elastance is a widely accepted means of modeling 
ventricular dynamics.  Elastance is the reciprocal of capacitance.  As the name implies, a time-
varying elastance is a periodic function with respect to time.  For the time-varying elastance 
model, the relationship between instantaneous ventricular volume, V(t), and instantaneous 
ventricular pressure, P(t), is given by [25]: 
 
[ ]DP(t)=E(t)× V(t)-V      (2-7) 
 
where E(t) is the time-varying elastance function and VD is unstressed volume of the ventricle.  
The elastance function, which rises and falls throughout the cardiac cycle, is an active element 
that is responsible for the energy of contraction in the CVS model. 
 
2.3.3.3 Ventricular Internal Resistance 
 Since the introduction of the time-varying elastance concept, studies have provided 
evidence that the ventricular pressure-volume relationship is not absolutely load independent 
[70-73].  These findings have led to the development of a ventricular model where the time-
varying elastance is in series with a pressure-dependent ventricular resistance.  This resistance 
was described by Shroff et al. [71, 74] as: 
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[ ]LV LV DR =K×E(t) V (t)-V      (2-8) 
  
where K is a proportionality constant (s/ml), and E(t) and VD are the same as in Equation 2-7.  
For the elastance-resistance model, the expression for P(t) is given by: 
 
[ ] [ ]{ }{ }D LV DP(t) = E(t)× V(t)-V R Q(t) = E(t)× V(t)-V 1-KQ(t)−   (2-8) 
 
where Q(t) is instantaneous ventricular outflow. 
2.3.4 Electrical Analog Models of Coupled Vascular-Ventricular System 
 Early coupled ventricle-vascular models were developed in the late sixties and early 
seventies by Beneken [75], Dick [76], Rideout [48], and McLeod [77]. McLeod’s Physiological 
Simulation Benchmark Experiment (PHYSBE) was an early electrical analog of the entire 
cardiovascular system, combining the heart and circulatory system.  McLeod made several 
assumptions when he simulated the CVS with an electrical analog: lumped parameters represent 
distributed properties of the CVS, and resistance and compliance of blood flow in vessels are 
linear.  McLeod also assumed that heart valves operate ideally, and atrial contraction and blood 
mass were negligible.  The model produces reasonable human pressure waveforms and is still 
currently used.  Others have improved upon McLeod’s model and have successfully produced 
more accurate physiological waveforms, usually accompanied by increasing complexity.  In fact, 
complex models are available that accurately describe all aspects of the CVS, including 
baroreflex, coronary blood flow and right/left ventricle interactions [78-81].   
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2.4 VAD MODELING 
 The interaction of a VAD with the native cardiovascular system has also been studied 
with the help of electric analogs [48, 78-86].  In this regard, the studies by Platt [79-81], Ferrari 
[80], and Jin [83], are of particular interest.  Each of these studies describes a model of a 
pulsatile, pneumatic VAD similar to the Thoratec® VAD. 
 The model developed by Platt assumed linear elements (compliance, resistance) to 
represent the VAD and a distributed CVS model including central nervous system (CNS) 
control.  Results focused on the optimal insertion site for VAD inlet cannulae and VAD control 
with respect to cardiac output and oxygen consumption.  The VAD model was controlled in both 
fixed rate and EKG triggered control modes, but not the fill-to-empty mode.  The study does not 
supply any validation information regarding the accuracy of the VAD model.   
 Ferrari et al. developed a model of the circulation system coupled with a pneumatic, 
pulsatile VAD.  The VAD was modeled as a compliant chamber, having a flat pressure volume 
relationship at intermediate volumes and steep pressure volume relationship when nearly full or 
nearly empty.  The pressure developed by the pneumatic driver was modeled using ideal gas 
laws.  This model was later used by De Lazarri [87] to investigate the effects of VAD control 
(fill-to-empty, fixed, and EKG triggered) on cardiovascular energetic variables (external work, 
pressure volume area, cardiac mechanic efficiency).  The model has since been copyrighted 
under the name CARDIOSIM®. 
 The Jin model uses a constant compliance bladder [83].  The focus of this particular study 
was to validate a method of valve modeling with time-vary resistors.  Rather than operating 
ideally, valves required some finite time to open and close.  The use of non-ideal valves was 
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shown to be considerable improvement for accurately matching experimental data.  A schematic 
of the electric analog with a systemic load is shown in Figure 9. 
 
 
Figure 9: Electric analog developed by Jin et al.  Pulsatile pneumatic VAD with systemic loading [83]. 
 
 Inlet and outlet cannulae were modeled with inductors (LI & LO) and resistors (RI & RO) 
in series.  The compliance of the bladder was represented with the capacitor CP.  The pneumatic 
drive pressure was modeled as a pressure source (PD) and resistor (RD) in series.  PD was a step 
function, which instantaneously switches between ejection pressure and filling pressure. 
 
2.5 BACKGROUND SUMMARY 
 Applications of pressure-volume relationships, heart failure and its clinical management, 
the current state of mechanical circulatory support, and ventricular recovery have been discussed.  
Recovery, while not fully understood, has the potential to alleviate many of the limitations of 
heart transplantation.  Several studies have been presented that propose methods for identifying 
possible recovery candidates and to monitor the recovery process.  Frequently, “off-pump” 
studies are used to assess native ventricular function by temporarily removing VAD support, 
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which is likely to increase the risk to the patient.  We believe that mathematical modeling-based 
analysis of the VAD-native cardiovascular system has a potential to provide valuable insights 
into the VAD-ventricle interaction and the recovery process.  Electric analog modeling of the 
cardiovascular system was introduced.  A better understanding of VAD-ventricle interactions 
could lead to improved methods for optimizing VAD operation and for assessing the native 
ventricular contractile function without the need for “off-pump” studies.  
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3.0 RESULTS AND DISCUSSION: MODEL DEVELOPMENT 
 The goal of the present study was to develop an accurate mathematical model of the 
Thoratec® pneumatic VAD in order to simulate its interactions with the left ventricle.  We have 
elected to model this VAD because all cases of recovery in the UPMC recovery studies have 
involved this device.  A model was proposed and experimentally tested in-vitro.  Improvements 
to the model were made as a result of in-vitro studies.  The final model was shown to accurately 
predict pressure and volume waveforms obtained experimentally.  The VAD model was then 
coupled to a native cardiovascular model to investigate VAD-left ventricular interaction. 
 In a clinical setting, one can record several hemodynamic waveforms in the presence of 
the VAD.  Although these waveforms contain a great deal of information, their interpretation is 
problematic because they depend on a number of unobservable factors: intrinsic properties of 
sub-systems (heart, circulation, VAD) and the interactions among these sub-systems.  
Mathematical models have potential to provide a better understating of the net function of 
interacting sub-systems and to extract intrinsic properties of each sub-system.  We have also 
hypothesized that a better understanding of the waveforms obtained from the VAD-ventricle 
system may reveal possible markers of recovery. 
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3.1 VAD MODEL 
A new model of the Thoratec® pneumatic VAD was developed.  This model shares some 
of the characteristics of previous models described in section 2.4, but also contains several new 
elements.  A series of experiments were performed to characterize the VAD.  The first of which 
was a static pressure-volume study. 
3.1.1 Static Study 
3.1.1.1 Methods 
 A static pressure-volume study was performed to characterize the behavior of the VAD 
bladder.  The slope of the pressure-volume relationship was used to estimate a value for the 
compliance of the bladder.  Under steady state, static conditions, water was added in steps of 5 
milliliters into the VAD bladder.  Simultaneous measurements of the internal pressure were 
taken with a 6F micro-tip pressure transducer (Millar Instruments, Houston, Texas). 
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3.1.1.2 Static Pressure-Volume Behavior 
-400
-300
-200
-100
0
100
200
300
400
500
600
0 20 40 60 80 100 120 140
VAD Bladder Volume (ml)
VA
D
 B
la
dd
er
 P
re
ss
ur
e 
(m
m
H
g)
 
Figure 10: Static pressure-volume relationship in the Thoratec® pneumatic bladder. 
 
 It can be seen that for volumes between 32 and 107 milliliters, there is very little pressure 
change.  The relationship of the VAD bladder pressure to volume is shown to be extremely linear 
in the volume this range (r2 = 0.98).  Volumes above ~107 ml cause much higher pressure 
increase per volume increase because of the stretching of the bladder and eventually because of 
the rigid outer case of the VAD.  Volumes below ~32 ml deviate from linearity because of 
resistance to collapse by the bladder.  The experimental data were approximated with piece-wise 
linear regions with five segments, as shown in Figure 11.  
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 Figure 11: Linear piece-wise approximation of VAD bladder compliance. 
 
 Clearly, the compliance of the bladder is not constant; it changes with bladder volume 
and can be approximated as a piece-wise linear function.  The piece-wise linear method will 
allow the state equation to remain with respect to volume.  Depending upon the calculated 
volume of the bladder, as determined in the mathematical model, one of the five linear regions 
can be chosen to quantify the compliance value (= inverse of the slope).   
 It was also necessary to know the bladder’s pressure-volume relationship with the 
presence of the external pneumatic pressure (Pd).  This was accomplished by repeating the static 
experiments under a variety of pneumatic pressures.  The findings from this experiment are 
shown in Figure 12. 
 
 33 
 
-400
-200
0
200
400
600
800
1000
0 20 40 60 80 100 120 140
VAD Bladder Volume (ml)
VA
D
 B
la
dd
er
 P
re
ss
ur
e 
(m
m
H
g)
Pd = 0 mmHg
Pd = 50 mmHg
Pd = 100mmHg
Pd = 150 mmHg
Pd = 200 mmHg 
Pd = 250 mmHg
 
Figure 12: Effect of pneumatic drive pressure (Pd) on VAD pressure-volume relationship under static 
conditions. 
 
 This plot shows a similar relationship as in Figure 10, with only a vertical offset 
equivalent to the pneumatic pressure applied.  From this experiment, it can be observed that 
under static conditions, instantaneous pressure in the bladder (Pp) can be estimated with the 
following equation:  
 
V D-VAD
V
P d
V -VC(V ) =
P - P
      (3-1) 
 
where VV is the volume of the VAD bladder, C(VV) and VD-VAD are the slope-1 and volume 
intercept, respectively, of the static pressure-volume curve as shown in Figure 11.  From these 
static data and an intuitive analogy of the physical system, the following electric analog model 
for the VAD is proposed (Figure 13). 
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Figure 13: Initial electric analog model of the VAD 
 
 The VAD bladder is a volume dependent capacitor with a value of C(VV).  C(VV) can be 
calculated using the piece-wise linear relationship in Figure 11.  The external pneumatic drive 
pressure, Pd, is a pressure source, and is added to the instantaneous bladder pressure Pp.  The two 
diodes represent the inlet and outlet valves. 
3.1.2 Dynamic Study 
3.1.2.1 Methods 
 To further investigate the behavior of the VAD, experiments were performed under 
dynamic conditions.  An in-vitro fluid circuit was used for this purpose, depicted in Figure 14. 
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 Figure 14: In-vitro setup of VAD with constant preload and variable afterload. 
 
 Inlet pressure Pi was created by a constant water level in a resevior.  Flow in and out of 
the Thoratec® bladder, Qi and Qo respectively, were measured with ultrasonic flow probes. 
(5/8’’ ID, Transonic Systems, Ithaca, New York).  The entire system was filled with water at 
ambient temperature.  The VAD ejected against an external hydraulic load consisting of a 
compliance (CS) and a resistance (RS).  The custom-made compliance chamber was a steel 
cylinder with a rubber, diaphragm lid pushing against a spring.  A needle valve (Deltrol Fluid 
Products, Bellwood, IL) served as the hydraulic resistor, RS, which could be altered by adjusting 
the valve orifice opening.  Characterization of the valve as a function of handle position can be 
found in Appendix D.  Pressure (PS) was recorded at the compliance chamber with a disposable 
pressure transducer (PX272, Edwards Lifesciences, Irvine CA) and an electronic monitor (870, 
Datascope Corp., Paramus NJ).  The VAD was fitted with a custom port to enable pressure 
measurements inside the bladder (PT) without interfering with the function of either the inlet or 
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outlet valves.  A 6F micro-tip pressure transducer (Millar Instruments, Houston, Texas) was 
inserted into the custom port.  Figure 15 shows the Thoratec® VAD fitted with the custom 
pressure port and flow probes. 
 
 
Pressure Port
Figure 15: Thoratec® pneumatic VAD, retrofit with pressure port.  
 
 A PC-based data acquisition system was used to acquire data.  Steady-state data were 
collected for a minimum of thirty seconds at a sampling rate of 200 Hz.  Multiple runs were 
performed, and afterload to the ventricle was adjusted by moving the position of the needle valve 
opening.  A series of experiments were performed under various resistances and different VAD 
control modes.  Table 1 outlines the different experimental conditions. 
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Table 1: Experimental Summary 
 
  Algorithm Rate (bpm) 
Resistance 
(mmHg*s/ml) 
Run 1 fixed 60 0.2 
Run 2 fixed 60 11.2 
Run 3 fixed 60 12.0 
Run 4 fixed 60 1.7 
Run 5 fixed 60 0.3 
Run 6 fixed 30 0.5 
Run 7 fixed 30 0.4 
Run 8 fill-to-empty N/A 0.2 
Run 9 fill-to-empty N/A 12.8 
Run 10 fill-to-empty N/A 12.9 
Run 11 fill-to-empty N/A 14.4 
Run 12 fill-to-empty N/A 1.9 
Run 13 fill-to-empty N/A 0.3 
Run 14 fill-to-empty N/A 0.5 
Run 15 fill-to-empty N/A 1.6 
Run 16 fill-to-empty N/A 1.5 
Run 17 fill-to-empty N/A 2.1 
 
 The experimental data were then compared to numerical results obtained from an electric 
analog.  Figure 16 shows the electric analog used to model the experimental system. 
 
 
Figure 16: Schematic of the in-vitro set up. 
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3.1.2.2 Dynamic Pressure-Volume Behavior 
 Figure 17 shows the actual dynamic pressure-volume relationship inside the VAD 
bladder.  Volume of the bladder was obtained by integrating the inlet flow waveform and 
subtracting the integral of the outlet flow waveform.  Initial volume was estimated by aligning 
the dynamic data with the static curve.    
 
 
Figure 17: Dynamic pressure-volume behavior of VAD bladder. 
 
 The dynamic pressure-volume relationship did not directly follow the static curve derived 
earlier: measured pressure was greater and less than predicted static pressure during the filling 
phase and ejection phase, respectively.  These deviations can be reconciled by the addition of 
resistive and inductive elements to the static model.  The improved electric analog model of the 
VAD is shown in Figure 18. 
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Figure 18: Updated electric analog model of the VAD to correct for dynamic observations. 
 
 The value of the series inductor LP was calculated using Equation 2-4.  The value of the 
resistor, RP, was adjusted until simulated model data closely matched the dynamic pressure curve 
shown in Figure 17.  Results of the revised VAD model are compared to the experimental 
dynamic pressure-volume relationship in Figure 19. 
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 Figure 19: Data for revised model, including bladder resistance (Rp) and inductance (Lp). 
 
 Qualitatively, it is observed that the revised model characterizes the dynamic pressure-
volume response of the VAD better than the static model.  There is still noticeable error in the 
regions of maximum and minimum volume, possibly a result on system non-linearities.  
3.1.2.3 Pneumatic Driver 
 Ejection and filling pressures for the driver can be set independently by the user.  In the 
clinical setting, ejection (PE) and filling (PF) pressures are typically set to 220 and -35 mmHg, 
respectively.  The Thoratec Dual Drive Console (DDC®) provides an analog signal 
corresponding to the pneumatic pressure, Pd (Figure 21).  It appeared that the dynamics of this 
pneumatic drive pressure can be modeled as a simple RC circuit (Figure 20). 
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 Figure 20: Electric analog model of the VAD pneumatic driver.  
 
 Values of VAD pneumatic driver parameters were estimated through least squares 
regression.  The optimal values of CD and RD were 4.0 ml/mmHg and = 0.01 mmHg*s/ml, 
respectively.  As illustrated in Figure 21, this simple model of the pneumatic driver can 
reproduce the experimental data quite well. 
 
 
Figure 21: Comparison of modeled pneumatic pressure and experimental data. 
 
 In our experiments, pressure outside the VAD bladder (Pex) was recorded directly and 
was found to be different from that reported by the DDC pneumatic pressure signal (Pd).  This 
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difference depended on dynamic conditions.  For example, when VAD volume decreased rapidly 
during ejection, Pex was less than Pd, presumably due to a rapid expansion of the air in the 
pneumatic system.  Ferrari et al. [87] modeled the properties of the pneumatic pressure with ideal 
gas laws.  We chose a different approach to this modeling problem.  It appeared that the ratio of 
Pex and Pd was proportional to the rate of change of fluid volume in the chamber ( V?V ).  Thus, the 
following equation was used to relate Pex to Pd: 
 
ex d VP =P ×αV?       (3-2) 
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Figure 22: Measured pneumatic pressure in the VAD chamber under (A) high afterload, and (B) low 
afterload. 
 
 An empirical estimate of α was 0.15 (s/ml).  Figures 22A and 22B show that the proposed 
modeling technique accurately describes measured Pex.  These illustrations correspond to two 
settings of VAD afterload.  In Figure 22A, afterload was 12.8 mmHg*s/ml and the user defined 
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console ejection pressure was 234 mmHg.  Because of the high afterload on the VAD, was 
low and therefore, Pex (Figure 22A) closely resembles Pd (Figure 21).  In contrast, Figure 22B 
shows a low afterload case, where output resistance was 0.5 mmHg*s/ml and the user defined 
console ejection pressure was 211 mmHg.  Due to high initial 
VV?
V
?V , there is a slower rise in Pex.  
When ejection nears completion and V?V  approaches zero, Pex reaches the prescribed user-
defined ejection pressure.  The proposed model reproduces this phenomenon. 
3.1.2.4 Cannula Modeling 
 Inlet and outlet cannula are modeled as an inductor and resistor in series.  Initial values 
for the cannula inductors were estimated using Equation 2-4 and a correction factor [48]:   
 
9 ρL=
4 A
 
?        (3-3) 
 
where is the fluid density, ?  is vessel length, and A is vessel cross sectional area.  Although 
Equation 3-3 provided a good estimate of outlet cannula inductance (Lo), inlet cannula 
inductance (Li) had to be increased by a factor of 1.75 to yield a good match between model-
based predictions and experimentally measured data. 
ρ
 Experimentally measured inlet cannula resistance, Ri, (Appendix C) was found to be 
greater than that estimated by Equation 2-2.  This may be due to turbulence, exit and enterance 
effects,  and non-ideal inlet valve (i.e., finite resistance in the open position).  The value for inlet 
resistance (Ri) listed in Table 2 matches the value found in literature [83].  While flows through 
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inlet and outlet cannulae were both turbulent (inlet NRe = 8000; outlet NRe = 24,000), the non-
linearities were more prominent for the outlet cannula.  Therefore, the outlet cannula resistance 
(Ro) was modeled as a flow-dependent resistor as described in Table 2. 
3.1.2.5 Leaky Valve Model 
 The VAD inlet (Di) and outlet (Do) valves were originally assumed to be ideal.  
Experimentally, this assumption was found to be incorrect; both valves exhibited reverse flows.  
The following scheme was followed to model leaky valves.  Consider the flow through the valve 
(D) in Figure 23.   
 
 
Figure 23: Schematic of flow through a vessel with a one-way valve 
 
 The expression for flow from P1 to P2 can be written as:  
 
[ ]1 2D P -PQ=
R
      (3-4) 
 
 A value of 1 is assigned to D when P1 is greater than P2; this is the open state of the valve 
wherein flow can occur in the forward direction (i.e., from P1 to P2; positive Q).  A value of 0 is 
assigned to D when Q first becomes less than zero; this is the closed state of the valve wherein 
flow in the reverse direction is prohibited.  Assigning a nonzero value to D when the valve is in 
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the closed state creates reverse flow or leakage through the valve.  The values for Di and Do 
(Table 2) were empirically chosen to provide best fit of negative flows at the VAD inlet and 
outlet.  
 Table 2 lists the values of all model parameters used in the modeling of the Thoratec® 
VAD system.  
 
Table 2: VAD model parameters 
 
 Description Value 
CD compliance of pneumatic drive line 4.0 ml/mmHg 
RD resistance of pneumatic drive line 0.0100 mmHg*s/ml 
Li inertance of Thoratec® inlet cannula 0.0854 mmHg*s2/ml 
Lo inertance of Thoratec® outlet cannula 0.0087 mmHg*s2/ml 
Ri resistance of Thoratec® inlet cannula 0.15 mmHg*s/ml 
Ro resistance of Thoratec® outlet cannula 0.05 + 0.00015*|Qo| 
RP resistance of Thoratec® Bladder 0.0500 mmHg*s/ml 
LP inertance of Thoratec® Bladder 0.0033 mmHg*s2/ml 
Di one-way inlet valve to Thoratec® blood sac 0.08 (closed) or 1 (open) 
Do one-way outlet valve to Thoratec® blood sac 0.03 (closed) or 1 (open) 
 
 
 
Figure 24: Final electric analog model of the VAD. 
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 The schematic diagram for the final VAD electric analog model is shown in Figure 24.  
The final VAD model contains a volume-dependent capacitor, two linear resistors, a flow-
dependent resistor, and three inductors.  The DDC model is an RC circuit whose output, Pc, is 
multiplied byα  to yield Pex. VV?
3.1.3 VAD Model Validation  
 VAD model parameters values were adjusted (diode leak parameters, inlet and outlet 
cannula resistances, and outlet cannula inductance) to fit a subset of experimental data (runs 1-4, 
Table 1).  Figures 25-27 show the model performance with respect to fitting experimental data 
(run 4, Table 1).  Here the VAD was controlled with a fixed rate of 60 per minute. 
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Figure 25: Comparison of experimental and model-based VAD volumes (run 4, Table 1). 
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Figure 26: Comparison of experimental and model-based VAD outflows (run 4, Table 1). 
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Figure 27: Comparison of experimental and model-based VAD bladder pressures (run 4, Table 1). 
 
 It can be seen that VAD pressure, flow, and volume are successfully modeled in the fixed 
rate mode.  The optimized model was then used to predict experimental data for conditions other 
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than those used for parameter adjustments.  Figures 28-29 show model-based predictions for one 
of the fill-to-empty mode experimental data (run 9, Table 1).  In this mode, ejection begins when 
the VAD bladder is full.  When full, the VAD triggers a magnetic hall switch, signaling the 
pneumatic drive to begin ejection [88]. 
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Figure 28: Comparison of experimental and model-based VAD bladder volumes (run 9, Table 1). 
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Figure 29: Comparison of experimental and model-based VAD bladder pressures (run 9, Table 1). 
 
 Similarly desirable predictability was noted with other experimental conditions.  Figure 
30 shows the model’s ability to predict stroke volume and VAD rate in all experimental 
conditions wherein the fill-to-empty mode was used (n=10). 
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Figure 30: Comparison of experimental data (fill-to-empty mode) and model-based predictions: (A) VAD rate 
(B) and stroke volume (solid line: line of identity). 
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 The percent error of each simulated point was measured against the respective 
experimental point.  These individual errors were averaged to obtain an overall, average percent 
error for both stroke volume and VAD rate.  The model accurately predicted stroke volume 
within 5.2±2.5% and VAD rate within 6.3±0.8%.  In summary, the proposed VAD model was 
found to have both descriptive and predictive validity. 
3.2 NATIVE CARDIOVASCULAR MODEL 
 A simple, lumped parameter electrical analog model (Figure 31) was chosen to represent 
the native cardiovascular system.  This model has been used previously in other studies [82, 84, 
89] and contains a left ventricle, systemic circulation, left atrium, and aortic and mitral valves.  
The left ventricle, systemic circulation, and left atrium are represented by a time-varying 
elastance (E(t)), a four-element Windkessel (RC, LS, CS, RS), and a passive compliance (CR), 
respectively.  The two valves are represented by ideal diodes in series with linear resistances. 
 
 
Figure 31: An electrical analog model of the native cardiovascular system.  
 
 51 
 
 52 
 
Table 3: Native cardiovascular model variables 
 
 Description 
VLV left ventricular volume* 
PLV pressure of the left ventricle 
PAO aortic pressure 
PAo aortic pressure 
PA peripheral arterial pressure* 
PR left atrial pressure* 
QV flow exiting the ventricle (same as QA) 
QA aortic flow* 
QM flow through the mitral valve 
QR atrial flow 
 * denotes state variable 
 
Table 4: Native cardiovascular model parameters 
 
 Description Normal Value 
RA resistance of the aortic valve 0.01 mmHg*s/ml 
DA aortic valve 0 or 1 
DM mitral valve 0 or 1 
RC characteristic resistance of the aorta 0.0398 mmHg*s/ml 
LS inertance of blood in large arteries 0.001025 mmHg s2/ml 
Cs systemic arterial compliance 2.896 ml/mmHg 
RS systemic arterial resistance 0.8738 mmHg*s/ml 
CR pulmonary and venous compliance 4.00 ml/mmHg 
En(tn) 
left ventricular normalized time varying active 
elastance  See Equation 3-5 
Emax left ventricular maximum active elastance  3.0 mmHg/ml 
Tmax 
Time to maximum left ventricular active 
elastance  See Equation 3-8 
VD left ventricular systolic unstressed volume  5.0 ml 
Ep left ventricular passive elastance  0.06 mmHg/ml 
V0 left ventricular diastolic unstressed volume  15.0 ml 
TCYCLE Cardiac cycle time  0.80 s 
 
 Parameter values for systemic circulation were taken from Yu [84].  The aortic (DA) and 
mitral (DM) valves are modeled as ideal diodes.  Therefore, following the discussion in section 
3.1.2.5, DA and DM take on values of either 1 (valve closed) or 0 (valve open).  The software 
coding implemented for valve modeling can be seen in detail in Appendix A. 
3.2.1 Left Ventricular Model 
 As described previously, the concept of time-varying elastance facilitates the modeling of 
ventricular active contraction (Equation 2-7).  Analytical approximations are now available, such 
as the one shown in Equation 3-5, to provide a mathematical form for the experimentally 
observed active elastance (Ea(t)) waveforms [90]. 
 
1.9
n
n n 1.9 21.9
n n
t
10.7E (t )=1.553174
t t1+ 1+
0.7 1.173474
                              
   (3-5) 
 
 En(tn) is a normalized curve that begins with a value of zero, and reaches a peak value of 
one at tn = 1, then returns to zero (Figure 32).  Ea(t) is given by: 
 
a MAX nE (t)=E *E (t )n       (3-6) 
 
n
CYCLE
tt =
0.2+0.1555*T
     (3-7) 
where EMAX, TMAX, and TCYCLE are maximum elastance, time to maximum elastance, and cardiac 
cycle time, respectively.  The expression in the denominator in Equation 3-8 is an empirically 
derived relationship between TMAX and TCYCLE (inverse of heart rate). 
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Figure 32: Normalized left ventricular elastance function. 
 
 Ea(t) is a model of the active contraction of the heart.  The heart also creates passive 
pressure as a result of the stretch of the ventricular muscle during diastole.  This passive element 
can be approximated by a linear pressure-volume relationship (i.e., constant passive elastance).  
Equation 3-8 shows an elastance based model of ventricular contraction where the active and 
passive behaviors are given by: 
 
[ ] [ ]LV a LV D p LV 0P (t)=E (t) V -V +E V -V     (3-8) 
  
where Ea(t) is the active elastance of the ventricle and Ep is the constant passive component of 
elastance.  VD and V0 are the volume-axis intercepts of the ESPVR and EDPVR, respectively. 
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Equation 3-8 can be simplified to combine the VLV term; 
 
 [ ]LV LV D pP (t)=E(t) V -V -E ∆V      (3-9) 
where E(t) = Ea(t) + Ep and V = V0 – VD.  This form of the equation is simplest to work with 
when using the state-space method for solving system differential equations (see section 3.2.2). 
∆
3.2.2 Governing System Differential Equations and Numerical Solution 
 The governing system differential equations for the native cardiovascular system (Figure 
31) are as follows: 
 
[ ]M MLV A A R LV D p
M M
D DV =-D Q + P - E(t) V -V -E ∆V
R R
  ?     (3-10) 
[ ]A A C A AA A A LV D
S S S
-[D R +R ] D DQ = Q - P + E(t) V -V -E ∆V
L L L p
  ?    (3-11) 
A A A
S S S S S
1 1 1P = Q - P + P
C R C R C
?
R       (3-12) 
[ ]M MR A R LV D p
R S R S R M R M
D D1 1P = P - + P + E(t) V -V -E ∆V
C R C R C R C R
       
?   (3-13) 
 
 Each equation above expresses the first derivative of a state variable as a function of state 
variables and model parameters.  Therefore, a solution for these four simultaneous differential 
equations can be obtained by numerical methods.  Figure 33 shows model-based results for a 
normal, human cardiovascular system (model parameter values in Table 4). 
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 Figure 33: Hemodynamic results obtained using the native cardiovascular model with normal parameter 
values. 
 
 Results show aortic pressures of 123/73/100 mmHg (systolic/diastolic/mean), LV 
volumes of 128/46 ml (EDV/ESV), and cardiac output of 6.2 L/min.  These values are typical for 
normal human physiology [91]. 
3.3 VAD-CARDIOVASCULAR MODEL 
 In this section, the VAD model is coupled to the model of the native cardiovascular 
system (CVS) to investigate VAD-ventricle dynamic interactions.   Figure 34 shows the coupled 
VAD/CVS model.  The inlet cannula of the Thoratec® is attached to the apex of the left ventricle 
at the node PLV.  Outlet flow from the Thoratec® returns to the CVS at the ascending aorta node, 
PAo. 
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 Figure 34: Electrical analog model of the coupled VAD and native cardiovascular system. 
 
 Two modifications were implemented in the coupled systems that were not present in the 
individual models.  VAD filling pressures are often below zero and because of this, ventricular 
collapse must be considered.  Otherwise the model would predict an impossible scenario of 
negative LV volume.  Collapse was modeled by exponentially increasing Ri as VLV approaches 
zero.  In the VAD/CVS system, Ri was not constant, but a function of VLV as described by the 
following expression: 
 
      (3-14) i i LVR  = R  + exp(-k*V )
 
A value of 0.25 was chosen for k.  This value allows the effect of collapse to be minimal at 
volumes above 15 ml, and rapidly reduces flow into the VAD as VLV falls below 15 ml, ensuring 
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that volume in the LV is never zero.  A plot of inlet resistance as a function of LV volume is 
shown in Figure 35. 
 
 
Figure 35: Ventricular collapse model; inlet VAD resistance as function of ventricular volume 
 
 A second modification was made to the native CVS model described earlier.  An 
additional compliance element (CAo) was added at the aortic node and aortic characteristic 
resistance (RC) was divided into R , placed before CAo, and RC, placed after CAo (Figure 34).  
The benefit of this modification is that the pressure (PAo) in the aorta becomes a state variable, 
which greatly reduces the complexity of writing the governing system differential equations.  It 
should be noted that this modification does not significantly alter the hydraulic input impedance 
(human heart rate frequency ranges) seen by the left ventricle (Figure 36) and therefore, has little 
effect on hemodynamic outcomes.   
C′
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 Figure 36: Original (A) and modified (B) cardiovascular models, with only the LV load elements shown. 
 
The input impedances of the original (Z0, Figure 36A) and modified (ZM, Figure 36B) are given 
by: 
 
0 C S S
S R
1Z =R +jωL + || R +
jωC jωC
  
1       (3-15) 
M C C S S
Ao S R
1 1Z =R + || R +jωL + || R +
jωC jωC jωC
1    ′        
  (3-16) 
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 Figure 37: Input impedance spectra of the original and modified models. 
 
The original cardiovascular model has previously been shown to compare well with human 
impedance spectra [82]. 
3.3.1 Governing System Differential Equations 
 The coupled VAD/CVS has nine state variables (Table 5) and four valves. 
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Table 5: VAD-CVS State Variables 
 
 Description 
VV Thoratec® pump sac volume 
Qi Thoratec® cannula inlet blood flow 
Qo Thoratec® cannula outlet blood flow 
VLV left ventricular volume 
PAo aortic pressure 
PA peripheral arterial pressure 
PR left atrial pressure 
QA aortic flow 
Pd pneumatic drive pressure from DDC 
 
 The governing system differential equations are as follows:  
 
d o
D D D D
1 1P = P - P
C R C R
  
?
d          (3-17) 
A A A
s s S s S
1 1 1P = Q - P + P
C C R C R
?
R        (3-18) 
[ ] A pA AAo LV O O D Ao o A
Ao A Ao A Ao A Ao Ao
D ED E(t) D 1 1P = V -V - [V -V ]- P + Q - Q
C R C R C R C C
?   (3-19) 
[ ] M pM MR A LV O O D
R S R M R M R M R S
D ED E(t) D1 1P = P - V -V + [V -V ]+ - P
C R C R C R C R C R R
   
?   (3-20) 
[ ]M A M A MLV R i LV O p O D Ao
M A M A M
D D D D D DV = P -Q - + E(t) V -V + + E [V -V ]+ P
R R R R R R
         
? A
A
o
 (3-21) 
V iV =Q -Q?           (3-22) 
C
A Ao A
S S S
R1Q = P - Q - P
L L L
?
A
1         (3-23) 
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[ ] i po P i P ii LV O O D
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o o P oi P i P
Ao i
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                      
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?   (3-24) 
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D R D L D R +RP + - Q
L +L L +L D L +L
D L D R +RD R+ - Q
L +L L +L D L +L
            
                
(3-25) 
 Details on the derivation of these equations are contained in Appendix B.  As before, this 
system of coupled differential equations was solved using numerical methods in the Matlab® 
environment.   
3.4 MODEL DEVELOPMENT SUMMARY 
 In this chapter, a model of a pulsatile pneumatic VAD was developed using ideas 
described in previous studies and new experimental measurements.  Parameter values for the 
VAD model were estimated first from physical principles and subsequently modified as needed 
based on experimental measurements.  The final VAD model was shown to be valid from both 
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descriptive and predictive perspectives.  For example, it predicted fill-to-empty VAD rate and 
stroke volume within 6% error.  The VAD model was then coupled to a model of native 
cardiovascular system.  In the following chapter, this coupled VAD/CVS model is used to 
investigate VAD-ventricular interaction. 
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4.0 RESULTS AND DISCUSSION: MODEL-BASED ANALYSIS 
 The validity of individual VAD and CVS models has been established in the previous 
chapter and in other sources[82, 84, 89].  Now we can combine these two models to examine the 
coupled VAD-CVS behavior, especially in the setting of heart failure.   
4.1 MODEL BASED RESULTS VS. CLINICAL DATA: A QUALITATIVE 
COMPARISON 
 As a starting point, model-based results were qualitatively compared to clinical data 
obtained from a study performed by Dr. John Gorcsan at UPMC.  Left ventricular chamber area 
(short-axis), peripheral arterial pressure (at the fingers), EKG, and VAD signals were recorded in 
the clinical study.  To facilitate comparisons, left ventricular volume (VLV) in the model-based 
studies was converted to chamber area using a spherical geometric model.  Peripheral arterial 
pressure (PA) is the closest model variable available to compare to clinical arterial pressure.  
Model-based results and clinical data from an individual patient are illustrated in Figure 38.  For 
model-based calculations, all cardiovascular parameters were the same as in Table 4, except for 
heart rate (equated to the observed heart rate) and left ventricular contractility (reduced to 
represent the failing left ventricle, EMAX = 1.0 mmHg/ml).  The VAD was operated in the 
modeling study according to the clinical settings, i.e., fill-to-empty mode with PE = 220 mmHg 
and PF = -35 mmHg. 
 Figure 38: Qualitative comparison of model-based results and clinical data.  Both sets of data are from a 
Thoratec® assisted LV. 
 
 Qualitatively, the patterns of hemodynamic responses are remarkably similar between the 
model-based results and clinical data.  Similar VAD rates (model: 71 bpm, clinical data: 66 bpm) 
and left ventricular area and arterial pressure ranges were observed.  The periodic dampening of 
the area curve is apparent in both the model-based results and clinical data, which is a result of 
the interaction between two independently running pumps: VAD and the native left ventricle.  
The contractions with smallest area changes correspond to co-pulsation (in phase contractions of 
VAD and native LV) and the largest area changes to counter-pulsations (out of phase 
contractions of VAD and native LV).  This phasic relationship between contractions of the two 
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pumps (often termed the analysis of synchrony) will be shown, through model-based analysis, to 
have a significant effect on left ventricular hydraulic load and mechanical work.  A more 
quantitative investigation was performed by varying key parameters of the cardiovascular model 
and observing their effects on the behavior of the coupled system, with a special emphasis on the 
analysis of synchrony.  
4.2 VAD CHARACTERISTIC FREQUENCY 
 In the fill-to-empty mode, the frequency of VAD contraction (i.e., VAD rate) is 
dependent on both VAD parameters (ejection and filling pressures, bladder and inlet and outlet 
cannula properties) and native cardiovascular parameters, including left ventricular contractility.  
We define VAD characteristic frequency (fC) as the rate at which the VAD will operate in the 
absence of active LV contraction, a condition corresponding to only one pump in the system.  As 
will be seen later, this concept of VAD characteristic frequency facilitates the interpretation of 
the coupled behavior.  The mathematical model was used to examine the influence of key 
cardiovascular parameters on VAD characteristic frequency.  Parameters were varied over a 
wide range of values around the normal human physiologic levels.  Figure 39 shows the 
dependency of fC on systemic vascular resistance (SVR), systemic compliance (CS), and passive 
LV elastance (EP).  In all of these simulations, LV active contraction was suppressed (EMAX = 0 
mmHg/ml). 
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Figure 39: The effect cardiovascular parameters of the characteristic frequency  
 
 These results demonstrate that VAD characteristic frequency changes by only 10% over a 
large range of cardiovascular parameters.  Thus, fC can be considered as an intrinsic VAD 
property, independent of individual patient’s cardiovascular characteristics. 
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4.3 ANALYSIS OF SYNCHRONY 
4.3.1 Left Ventricular Contractility 
 Clearly, the VAD operating in the fill-to-empty mode will not function below fC.  This 
implies that the left ventricle must beat above fC in order to be synchronized with the VAD.  
Synchrony can occur above the fC if ventricular contraction significantly contributes to VAD 
filling (a condition of counter-pulsation).  Consequently, a stronger left ventricle (i.e., greater 
EMAX) has a greater potential to synchronize VAD rate to native heart rate and vice versa.   
 To vary left ventricular contractility in the model, the value of the maximum active 
elastance (EMAX) was altered.  The following plot shows the effect of EMAX variations on VAD 
rate in the fill-to-empty mode. 
 
 
Figure 40: Model-based results: Effects of contractility on VAD rate. 
 
 The model results indicate that for a relatively strong heart (say, EMAX = 2.0 mmHg/ml), 
the VAD rate completely synchronizes with the native heart rate of 85 bpm and there is no 
change over time.  As contractility decreases, the VAD rate is unable to synchronize completely 
because the LV does not provide sufficient VAD filling within a single contraction.  The VAD 
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rate in these circumstances is always lower than the native heart rate.  Furthermore, as EMAX 
decreases, the average VAD rate decreases and the frequency of cyclic VAD rate variations 
increases.  The periodic minimum points of VAD rate correspond with VAD-ventricle co-
pulsations (asynchronous behavior). 
 To further examine the effects of LV contractility on the behavior of the coupled system, 
we can take a closer look at model-based hemodyanmic data for a strong heart (EMAX = 3.0 
mmHg/ml) and a weak heart (EMAX = 1.0 mmHg/ml) (Figure 41).   
 
 
Figure 41: Model-based results (steady state data): strong heart vs. weak heart. 
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 In the case of the strong heart (Figure 41, left panels), LV contraction is sufficiently 
powerful to totally fill the VAD within a single beat and therefore, the VAD rate completely 
synchronizes with the native heart rate.  Steady state LV and pneumatic pressure waveforms 
clearly indicate that the LV and VAD are operating in the counter-pulsation mode (i.e., 
completely synchronized).  In contrast, a great deal of asynchrony is seen with the weak heart 
(Figure 41, right panels).  Here the LV is unable to completely fill the VAD in a single 
contraction and therefore, VAD rate is always lower than the native heart rate.  In addition, VAD 
rate oscillates over time depending on the relative degree of synchrony (or asynchrony): regions 
of co-pulsations (more asynchrony) have lower VAD rate and regions of counter-pulsations 
(more synchrony) have greater VAD rate.  Significant beat-to-beat changes in LV volume and 
pressure data can also be observed: increased LV end-systolic volume and pressure in regions of 
co-pulsations and vice versa.  Thus, LV hydraulic load is greater during co-pulsations as 
compared to that during counter-pulsation.  This asynchronous behavior is more frequent as the 
heart becomes progressively weaker, resulting in a greater occurrence of co-pulsating beats with 
greater hydraulic load.  At this point, one would be tempted to conclude that the asynchronous 
behavior (i.e., cyclic changes in VAD rate, LV volume or area) can be used as an index of native 
LV contractility.  However, results presented below indicate that factors other than LV 
contractility contribute to the asynchronous behavior. 
4.3.2 Native Heart Rate 
 The rate at which the native heart contracts also plays a significant role in determining 
the synchrony of the VAD-ventricle system.  Figure 42 shows the effects of native heart rate on 
synchrony for a weak heart (EMAX = 1.0 mmHg/ml).  These data indicate that the coupled 
behavior can be synchronous at some native heart rate (75 bpm in Figure 42), and asynchrony 
ensues above and below this rate. 
 
 
Figure 42: Effect of native heart rate on VAD-ventricle synchrony on a weak heart. 
 
 A similar pattern was observed for a strong heart (EMAX = 3.0 mmHg/ml) (Figure 43).  
While the lower threshold for appearance of asynchrony was unchanged (60 bpm), the upper 
threshold increased (95 bpm for strong heart vs. 85 bpm for the weak heart).  
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 Figure 43: Effects of native heart rate on a strong heart. 
 
 The characteristic frequency (fC) for this system was 65 bpm.  The invariant lower 
threshold is related to fC.  If the native heart rate is below fC, the minimum VAD rate is equal to 
fC, periodically going above due to contributions by the native LV contraction to its filling.  This 
assertion is supported by data in Figures 42-43 wherein the minimal VAD rate is always close to 
fC. 
 The VAD-CVS model predicts that asynchronous behavior does not uniquely imply a 
weaker LV; native heart rate is also an independent determinant.  Synchronous behavior is 
observed over a range of native heart rates.  The lower limit of this range is governed by the 
characteristic frequency and the upper limit is dependent on the LV contractility: higher EMAX 
yields higher upper limit and vice versa.   
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4.3.3 Systemic Vascular Resistance 
 The effects of systemic vascular resistance (SVR) on VAD-ventricle synchrony were also 
investigated.  Figure 44 shows two examples, low SVR (0.53 mmHg*s/ml) and normal SVR 
(0.87 mmHg*s/ml), both with native heart rate of 85 bpm and EMAX = 1.0 mmHg/ml (weak 
heart). 
 
 
Figure 44: Effects of SVR on VAD-ventricle synchrony. 
 
 A monotonic relationship between SVR and synchrony was observed.  For a given EMAX 
and native heart rate, asynchrony can be attained at a certain SVR and this asynchrony can be 
abolished by lowering SVR.  Increasing SVR has little effect on end-ejection VAD volume 
because within physiologic limits, VAD contraction is powerful enough to eject all of VAD 
volume during a single contraction.  In contrast, increasing SVR reduces left ventricular filling 
pressure and consequently, reduces the rate of VAD filling and VAD rate in the fill-to-empty 
mode. 
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4.3.4 Left Ventricular Diastolic Stiffness 
 The slope of the passive pressure-volume relationship (EP) was also varied to examine the 
effects of a stiff or flaccid left ventricle.  Three different values of EP were investigated: flaccid 
LV (0.02 mmHg/ml), normal LV (0.06 mmHg/ml), and stiff LV (0.18 mmHg/ml).   
 
 
Figure 45: Effects of Ep on VAD-ventricle synchrony (strong heart) 
 
 Figure 45 illustrates that variations in EP, within the range of 0.02 to 0.18, do not 
significantly affect the VAD-ventricle synchronous behavior.  All three examples are shown to 
be in synchrony with the native heart rate of 85 bpm.  As expected, increasing EP caused LV 
end-diastolic volume to be reduced (Figure 46), but these effects do not have any impact on 
VAD filling rate. 
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 Figure 46: Effects of Ep on LV Volume (strong heart).  For clarity volume data for the normal Ep value (0.06 
mmHg/ml) are not shown.  
 
 Effects of variations in EP in the case of a weak heart are shown in Figure 47.  In contrast 
to the strong heart (Figure 45), asynchronous behavior exists in this example.  However, changes 
in EP, once again, do not affect this behavior in that asynchronous behavior is observed for all EP 
values. 
 
Figure 47: Effects of Ep on VAD-ventricle synchrony (strong heart) 
 
 In the weak heart case, end-diastolic volumes were again lower when EP was increased 
(data not shown).  From these results we can conclude that unlike LV EMAX, native heart rate, 
and SVR, EP does not significantly affect VAD-ventricle synchrony. 
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4.4 MODEL BASED ANALYSIS SUMMARY 
 Model-based results were qualitatively compared to clinical data obtained from a patient 
with Thoratec® VAD.  Similarities were visible in both LV chamber area and peripheral 
pressure signals.  The VAD rates were also similar (model: 71 bpm, clinical data: 66 bpm).  The 
periodic dampening of LV chamber area was observed to coincide with VAD-ventricle co-
pulsations in both the model and clinical results.  To quantitatively investigate the occurrence of 
co-pulsating beats (analysis of synchrony) of the VAD and ventricle, an investigation of the 
model behavior with respect to key cardiovascular parameters was performed.  The results of the 
model behavior investigation revealed that the likelihood of VAD-ventricle synchrony is 
determined by a complex interaction of contractility, cardiovascular parameter (such as SVR), 
and native heart rate.  A graphical summary of these interactions is given in Figure 48. 
 
 
Figure 48: Graphical summary of the influences on VAD-ventricle synchrony. 
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 The vertical broken line indicates the characteristic frequency (fC).  This point represents 
the minimal native heart rate below which VAD-ventricle synchrony will not exist.  Our model-
based analysis indicates that fC is essentially independent of cardiovascular parameters and thus, 
an intrinsic property of the VAD.  There is a also a maximum native heart rate above which 
VAD-ventricle synchrony will not exist; as shown by the tip of the synchrony bars (shaded 
areas).  Unlike fC, the maximum native heart rate for synchronous behavior is governed by 
cardiovascular parameters (EMAX and SVR).  To achieve synchrony, the native heart rate must be 
within the range determined by fC, EMAX and SVR.  Asynchrony ensues with native heart rate 
outside this range, resulting in beats with co-pulsations and increased ventricular loading. 
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5.0 RECOMMENDATIONS 
 While the similarities between simulation and clinical data are promising, there is room 
for improvement.  It is possible that clinical phenomena could be better captured with greater 
complexity of the circulation model.  Improved detail of peripheral pressure would allow for 
better comparison of model results with the peripheral pressure measurements made clinically 
(e.g., fingertip pressure).  Also, a model of a four-chamber heart will allow for the investigation 
of left and right heart failure and the role of atrial contractions.   
 Results from model behavior analysis have demonstrated that contractility, heart rate, and 
systemic vascular resistance are each independent determinants of synchrony between the VAD 
and ventricle.  However, in the human body, contractility, heart rate, and SVR are controlled by 
the central nervous system (CNS).  Baroreflex is a feedback system of the CNS which adjusts 
heart rate and SVR in order to regulate systemic blood pressure.  Mathematical models of 
baroreflex control are available, and implementing this process into our current VAD-CVS 
model may provide further insights into VAD-ventricle interactions. 
 The clinical utility of our model-based analysis of the VAD-CVS system needs to be 
examined.  It is possible that changes in the degree of synchrony over time can provide 
information about the ventricular recovery process.  Heart failure is most commonly 
characterized by a decrease in contractility (EMAX) and increase in SVR.  The results of model-
based analysis indicate that VAD-ventricle synchrony is highly responsive to the reversal of 
these characteristics of heart failure.  Because SVR is readily measured by non-invasive 
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techniques, it is then conceivable that changes in EMAX could be extracted from analysis of the 
temporal variations observed in synchrony.  However, longitudinal clinical data and further 
analysis would be required to address these issues. 
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APPENDIX A 
 
 
 
 
MATLAB CODE 
 
 
%VADSIM.M 
% THIS CODE IS THE PRIMARY CODE FOR WHICH TO RUN THE  
% CARDIOVASCULAR SIMULATOR 
 
% CLEAR THE WORKSPACE 
%clear all 
 
%DEFINE ALL MODEL PARAMETERS AS GLOBAL SO THAT THEY MAY BE USED 
IN RUNKUT4.M TO FIND SOLUTIONS 
global Dm Rm Da Ra Rc Ls Cs Rs Cr Rp Lp0 Lp1 Rv Di Do i Ev 
global Li Lo Ri Ro0 Ro1 Ro2 
 
%Cardiovascular System Model ADOBPTED FROM Breitenstein; 
 
%SET INTIAL VALUES OF CERTAIN PARAMETER WHICH ARE DISPLAYED ON 
THE FIRST SCREEN 
HR=75;          % HR-Heart rate(bpm)[normal-75;weak-120] 
Rs=0.83;        % Rs-system resistance;(0.83-normal,weak; 1.4-
severly weak without pump; 0.83-severly weak with 
pump)(mmHg.sec/mL) 
V_total=370;    % total blood volume; (280-normal)(mL) + 
Vvad(1)+Vao(1) 
Cs=1.33;        % Systemic Complinace (ml/mmHg) 
t_eject = 300;  % Ejection time for VAD in fill-to-empty 
operation 
end_t=6;        % end of simulation time 
 
Ptf = -35;      % Filling pressure (vacuum) for Thoratec (mmHg) 
Pte = 220;      % Ejection pressure for Thoratec (mmHg) 
open = 1; 
 
colors = ['b','r','g','c','m','k','y']; 
shapes(1,1:length(colors)) = colors; 
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shapes(2:3,1:length(colors)) = '-'; 
 
zoomswitch=0; 
ind=0; 
Hf_fig = figure('Name',sprintf('Cardiovascular Simulator')); 
set(gcf,'Menubar',menubar); 
 
%fullscreen(Hf_fig); 
 
Ha_ax1=axes; 
set(Ha_ax1,'position',[.08 .78 .9 .2],... 
    'FontSize',8,... 
    'Box','on',... 
    'XTickLabelMode','manual','XTickMode','auto',... 
    'XTickLabel',[]) 
 
Ha_ax2=axes;  
set(Ha_ax2,'position',[.08 .53 .9 .2],... 
    'FontSize',8,... 
    'Box','on',... 
    'XTickLabelMode','manual','XTickMode','auto',... 
    'XTickLabel',[]) 
 
Ha_ax3=axes;  
set(Ha_ax3,'position',[.08 .28 .9 .2],... 
   'FontSize',8,... 
   'Box','on') 
 
HRstr = num2str(HR); 
Tstr  = num2str(end_t); 
Emax0 = 3; 
Rsstr = num2str(Rs); 
Cs_str = num2str(Cs); 
EtMax_str = num2str(Emax0); 
Ptfstr = num2str(Ptf); 
Ptestr = num2str(Pte); 
t_ejectstr = num2str(t_eject); 
 
istr = 1; 
r  = .08; 
up = .20; 
w  = .05; 
h  = .03; 
Qo = 0; 
 
Hc_HRedit = 
uicontrol(Hf_fig,'Style','Edit','String',HRstr,'units','normalize
d','Position',[r+0.1 up-.04 w h]); 
Hc_HRtext = uicontrol(Hf_fig,'Style','Pushbutton','String','Heart 
Rate','Fontweight','Bold','units','normalized',... 
    'Fontsize',10,'Position',[r up-.04 w+.03 h],... 
    'Callback','HR_help = helpdlg(''HR-Heart rate(bpm)[normal-
75;weak-120]'',''Heart Rate'');'); 
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Hc_Tedit = 
uicontrol(Hf_fig,'Style','Edit','String',Tstr,'units','normalized
','Position',[r+0.1 up-.08 w h]); 
Hc_Ttext = 
uicontrol(Hf_fig,'Style','Pushbutton','String','Time','Fontweight
','Bold','units','normalized',... 
    'Fontsize',10,'Position',[r up-.08 w+.03 h],... 
    'Callback','T_help = helpdlg(''Time of Simulation 
(seconds)'',''Simulation Time'');'); 
 
Hc_Rsedit = 
uicontrol(Hf_fig,'Style','Edit','String',Rsstr,'units','normalize
d','Position',[r+0.3 up w h]); 
Hc_Rstext = 
uicontrol(Hf_fig,'Style','Pushbutton','String','SVR','Fontweight'
,'Bold','units','normalized',... 
    'Fontsize',10,'Position',[r+.2 up w+.03 h],... 
    'Callback','Rs_help = helpdlg(''Rs-system resistance;(0.83-
normal,weak; 1.4-severly weak without pump; 0.83-severly weak 
with pump)(mmHg.sec/mL)'',''Systemic Resistance'');'); 
 
Hc_Vtedit = 
uicontrol(Hf_fig,'Style','Edit','String',Cs_str,'units','normaliz
ed','Position',[r+0.3 up-.035 w h]); 
Hc_Vttext = 
uicontrol(Hf_fig,'Style','Pushbutton','String','Cs','Fontweight',
'Bold','units','normalized',... 
    'Fontsize',10,'Position',[r+.2 up-.035 w+.03 h],... 
    'Callback','Rs_help = helpdlg(''Compliance; (1.33-
normal)(mmHg/ml)'',''Systemic Compliance'');'); 
 
Hc_Etedit = 
uicontrol(Hf_fig,'Style','Edit','String',EtMax_str,'units','norma
lized','Position',[r+0.3 up-.07 w h]); 
Hc_Ettext = uicontrol(Hf_fig,'Style','Pushbutton','String','E(t) 
max','Fontweight','Bold','units','normalized',... 
    'Fontsize',10,'Position',[r+.2 up-.07 w+.03 h],... 
    'Callback','Rs_help = helpdlg(''Maximum Elastance; (3-
normal)(mmHg/ml)'',''Elastance'');'); 
 
Hc_Ejectedit = 
uicontrol(Hf_fig,'Style','Edit','String',t_ejectstr,'units','norm
alized','Position',[r+0.5 up-.06 w h],'Visible','on'); 
Hc_Ejecttext = 
uicontrol(Hf_fig,'Style','Pushbutton','String','Eject 
Time','Fontweight','Bold','units','normalized',... 
    'Fontsize',10,'Position',[r+.4 up-.06 w+.03 
h],'Visible','on',... 
    'Callback','Pi_help = helpdlg(''Thoratec Ejecting Time 
(sec)'',''Thoratec Eject Time'');'); 
 
Hc_Ptfedit = 
uicontrol(Hf_fig,'Style','Edit','String',Ptfstr,'units','normaliz
ed','Position',[r+0.5 up-.12 w h],'Visible','on'); 
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Hc_Ptftext = uicontrol(Hf_fig,'Style','Pushbutton','String','Fill 
Pres.','Fontweight','Bold','units','normalized',... 
    'Fontsize',10,'Position',[r+.4 up-.12 w+.03 
h],'Visible','on',... 
    'Callback','Pi_help = helpdlg(''Thoratec Vacuum Setting 
(mmHg)'',''Thoratec Vacuum'');'); 
 
Hc_Pteedit = 
uicontrol(Hf_fig,'Style','Edit','String',Ptestr,'units','normaliz
ed','Position',[r+0.5 up-.18 w h],'Visible','on'); 
Hc_Ptetext = 
uicontrol(Hf_fig,'Style','Pushbutton','String','Eject 
Pres.','Fontweight','Bold','units','normalized',... 
    'Fontsize',10,'Position',[r+.4 up-.18 w+.03 
h],'Visible','on',... 
    'Callback','Pi_help = helpdlg(''Thoratec Ejection Setting 
(mmHg)'',''Thoratec Ejection'');'); 
 
Hc_zoom = 
uicontrol(Hf_fig,'Style','Pushbutton','String','Zoom','Fontweight
','Bold','units','normalized',... 
    'Fontsize',10,'Position',[r+.4 up w+.03 h],... 
    'Callback','zoomfunc'); 
 
Hc_PumpMenu = 
uicontrol(Hf_fig,'Style','popupmenu','String','Pneumatic|Electric
/Pulsatile|Axial|Centrifugal Pump',... 
    'units','normalized','Position',[r up-0.0 3*w 
h],'Callback','popupselect'); 
 
Hc_PumpOn = uicontrol(Hf_fig,'Style','radiobutton','String','Pump 
On','Backgroundcolor',get(Hf_fig,'color'),... 
    'units','normalized','Position',[r up-0.13 3*w 
h],'value',1,'Fontsize',12,'Callback','set(Hc_PumpOn,''value'',1)
;set(Hc_PumpOff,''value'',0)'); 
 
Hc_PumpOff = 
uicontrol(Hf_fig,'Style','radiobutton','String','Pump 
Off','Backgroundcolor',get(Hf_fig,'color'),... 
    'units','normalized','Position',[r up-0.17 3*w 
h],'Fontsize',12,'Callback','set(Hc_PumpOn,''value'',1);set(Hc_Pu
mpOff,''value'',1);set(Hc_PumpOn,''value'',0)'); 
 
Hc_VADsim = uicontrol(Hf_fig,'Style','pushbutton','String','Run 
Simulation',... 
    'units','normalized','Position',[r+.8 up-0.12 2*w 
2*h],'CallBack','runsim'); 
 
Hc_PlotOver = 
uicontrol(Hf_fig,'Style','radiobutton','String','Overlay 
Plot','Value',1,... 
    'units','normalized','Position',[r+.8 up-0.0 2*w 
2*h],'Backgroundcolor',get(Hf_fig,'color'),... 
    'CallBack','set(Hc_PlotNew,''value'',0);'); 
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Hc_PlotNew = uicontrol(Hf_fig,'Style','radiobutton','String','New 
Plot',... 
    'units','normalized','Position',[r+.8 up-0.04 2*w 
2*h],'Backgroundcolor',get(Hf_fig,'color'),... 
    'CallBack','set(Hc_PlotOver,''value'',0);'); 
 
Hc_PlotPv = uicontrol(Hf_fig,'Style','radiobutton',... 
    'units','normalized','Position',[r-.06 up+0.04 w 
h],'Backgroundcolor',get(Hf_fig,'color'),... 
    'value',1,'String','Pv'); 
 
Hc_iedit = 
uicontrol(Hf_fig,'Style','Edit','units','normalized',... 
    'Backgroundcolor',get(Hf_fig,'color'),'Position',[r+0.65 up w 
h]); 
Hc_index = 
uicontrol(Hf_fig,'Style','text','String','Index','units','normali
zed','Fontweight','Bold',... 
    'Backgroundcolor',get(Hf_fig,'color'),'Position',[r+0.6 up-
.002 w h]); 
Hc_Da = 
uicontrol(Hf_fig,'Style','text','String','Da','units','normalized
','Fontweight','Bold',... 
    'Backgroundcolor',get(Hf_fig,'color'),'Position',[r+0.6 up-
.042 w h]); 
Hc_Dm = 
uicontrol(Hf_fig,'Style','text','String','Dm','units','normalized
','Fontweight','Bold',... 
    'Backgroundcolor',get(Hf_fig,'color'),'Position',[r+0.6 up-
.082 w h]); 
Hc_Di = 
uicontrol(Hf_fig,'Style','text','String','Di','units','normalized
','Fontweight','Bold',... 
    'Backgroundcolor',get(Hf_fig,'color'),'Position',[r+0.6 up-
.122 w h],'Visible','on'); 
Hc_Do = 
uicontrol(Hf_fig,'Style','text','String','Do','units','normalized
','Fontweight','Bold',... 
    'Backgroundcolor',get(Hf_fig,'color'),'Position',[r+0.6 up-
.162 w h],'Visible','on'); 
Hc_Dastatus = 
uicontrol(Hf_fig,'Style','Edit','units','normalized','Position',[
r+0.65 up-.04 w h]); 
Hc_Dmstatus = 
uicontrol(Hf_fig,'Style','Edit','units','normalized','Position',[
r+0.65 up-.08 w h]); 
Hc_Distatus = 
uicontrol(Hf_fig,'Style','Edit','units','normalized','Position',[
r+0.65 up-.12 w h],'Visible','on'); 
Hc_Dostatus = 
uicontrol(Hf_fig,'Style','Edit','units','normalized','Position',[
r+0.65 up-.16 w h],'Visible','on'); 
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Hc_meanQstr = uicontrol(Hf_fig,'Style','text','String','mean 
Qo','units','normalized','fontsize',12,... 
    'Backgroundcolor',get(Hf_fig,'color'),'Position',[r+0.2 up-
.16 w*2 h]); 
 
Hc_meanPstr = uicontrol(Hf_fig,'Style','text','String','mean 
Ps','units','normalized','fontsize',12,... 
    'Backgroundcolor',get(Hf_fig,'color'),'Position',[r+0.2 up-
.12 w*2 h]); 
 
Hc_meanQ = 
uicontrol(Hf_fig,'Style','text','String','N/A','units','normalize
d','fontsize',12,... 
    'Backgroundcolor',get(Hf_fig,'color'),'Position',[r+0.3 up-
.16 w*2 h]); 
 
Hc_meanP = 
uicontrol(Hf_fig,'Style','text','String','N/A','units','normalize
d','fontsize',12,... 
'Backgroundcolor',get(Hf_fig,'color'),'Position',[r+0.3 up-.12 
w*2 h]); 
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%  RUMSIM.M EXECUTED BY CLICKING THE RUN SIMULATION BUTTON  
%  ON THE MAIN SCREEN 
 
%SAVE PREVIOUS RUN FOR COMPARISON IF DESIRED 
if length(Qo) > 10 
    Qo_last = Qo; 
    Qi_last = Qi; 
    Qa_last = Qa; 
    Pt_last = Pt; 
    Pexternal_last = Pexternal; 
    Pp_last = Pp; 
    Pv_last = Pv; 
    Vlv_last = Vlv; 
    Pa_last = Pa; 
    Pr_last = Pr; 
    Vvad_last = Vvad; 
    Pao_last = Pao; 
end  
% CLEAR WORKSPACE IN CASE THE PREVIOIUS SIMULATION RUN WAS 
LONGER THAN THE CURRENT RUN 
clear A B x Vd te Pp Qi Qo Ps Pt Vvad Px Pexternal Pv Pa Pao Qa 
Pr Pex Vlv Din Dout Daorta Dmitral xx xxdot Vao Vp 
zoomswitch=1; 
zoomfunc 
set(Hf_fig,'WindowButtonDownFcn','Bdown','WindowButtonUpFcn','B
up');  
%COLLECT PARAMETER VALUES AS DEFINED FROM THE USER ON THE MAIN 
SCREEN 
HR       = str2num(get(Hc_HRedit,'string')); 
end_t    = str2num(get(Hc_Tedit,'string')); 
Rs       = str2num(get(Hc_Rsedit,'string')); 
Cs       = str2num(get(Hc_Vtedit,'string')); 
Emax0    = str2num(get(Hc_Etedit,'string')); 
Pte      = str2num(get(Hc_Pteedit,'string')); 
Ptf      = str2num(get(Hc_Ptfedit,'string')); 
t_eject  = str2num(get(Hc_Ejectedit,'string')); 
pump     = get(Hc_PumpMenu,'value')-1; 
 
%BUILD TIME ARRAY FOR SIMULATION 
%Simulation Time--T; 
start_t=0; 
step=0.001; 
t_eject_n = round(0.001*t_eject/step); 
t_eject_nc = t_eject_n; 
 
%Thoratec Parameters 
%1 mmHg = 1.35951 gmf/cm^2 
%g = 980 cm/s^2; 1 mmHg = 1359.5 gm/cm*s^2 
%1 gm/cm*ml = 1359.5 mmHg*sec^2/ml  
 
eta_blood  = 0.0007501;       %mmHg.sec/ml or 3 cP 
eta_H2O    = 0.000250;        %mmHg.sec/ml or 1 cP   
Tmax_vol = 110;               %ml 
Vd_vad   = 107;               %ml 
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%Human Values for Cannula 
Tcannula_length_out = 32;     %cm 
Tcannula_length_in  = 24;     %cm 
 
%LVAD cannula diameter = 1.8 cm 
Tcannula_area   = (0.9^2)*pi; %cm^2 
rho_blood = 1;                %gm/ml 
 
%GEOMETRY VALUES FOR Rp AND Lp 
Thoratec_length=10;           %cm 
Thoratec_area=5;              %cm 
 
 
%INITIAL VALUES OF INLET AND OUTLET RESISTANCE FOR THORATEC 
CANNULA 
Ri = .15 
Ro = .05 
 
%EXPRESSION OF FINDING INDUCTANCE VALUES IN THE MODEL 
Li  = 
(9/4)*(rho_blood*Tcannula_length_in)/(1359.5*Tcannula_area);   
%Rideout text 
Lo  = (rho_blood*Tcannula_length_out)/(1359.5*Tcannula_area);  
%Rideout text 
Lp = (9/4)*(rho_blood*Thoratec_length)/(1359.5*Thoratec_area); 
Li = Li*1.75 
Lo = Lo 
 
 
Rp =.05;    % Resistor in the VAD (mmHg*s/ml) 
Cp = 2.0;   % ml/mmHg as estimated from PV experiments 
Rd = .01;   % Resistance of Drive line air;   
Cd = 4;     % Complinace of Drive line air; 
 
%cardiovascular system model parameters (taken from 
BREITENSTEIN); 
Rm = 0.005;         % Rm-mitral valve open;(mmHg.sec/mL) 
Ra = 0.001+.005;    % Ra-aortic valve open;(mmHg.sec/mL) 
Rc = 0.0398-.005;   % Rc-characteristic 
resistance;(mmHg.sec/mL) 
Ls=5e-4;            % Ls-inertance of blood in 
aorta;(mmHg.sec^2/mL) 
%Cs=1.33;           % Cs-system compliance;(mL/mmHg) 
Cao = .2;           % Aortic Complinace (ml/mmHg) 
Cr=4.4;             %Cr-pulmonary compliance;(mL/mmHg) 
Vd=5;               % isovolume; 
 
%generate LV elastance for given Emax0,Ed0,and HR; 
%Left Venticular function parameters 
clear Ev 
 
Ep = 0.06;  %simplified linear passive pressue relationship 
Vo = 15;    %x-intercept of linear EDPVR 
dV = Vo-Vd; 
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%Uses the already created Time scale 
    T=start_t:step:end_t; 
    n=length(T); 
    Ea=EofT(T,HR,Emax0,step); 
 
%Initialize variable for the first iteration of the simulation 
 
Pt(1)=0; 
Px(1)=0; 
Vvad(1)=107; 
Pex=0; 
Pi=8; 
Pe=8; 
Pd=0; 
 
bladder_comp(1) = Cp;  
Pp(1)=(Vvad(1)-Vd_vad)/Cp; 
Ps(1)=80; 
Qi(1)=0; Qo(1)=0; 
V_sum(1)=Cs*Ps(1)+Vvad(1); 
Vs(1)=Cs*Ps(1); 
Di=0;Do=0; 
Pexternal(1)=Pd(1); 
Qs(1)=0; 
Qv(1)=0; 
Qe(i)=(Ps(1)-Pe)/Rs; 
mode = 1; 
T=start_t:step:end_t; 
n=length(T); 
 
%RUN THE DESIRED SET OF DIFFERENTIAL EQUATIONS 
% THORATEC_CARDIO_FINAL RUNS THE VAD/CVS COUPLED MODEL 
% THORATEC3A RUNS THE IN-VITRO EXPERIMENTAL SETUP 
 
thoratec_cardio_final 
 
% FOLLOWING CODE IS USED TO PLOT THE RESULTS 
% OF THE DIFFERENTIAL EQUATIONS RUN IN THE  
% ABOVE STEP 
 
if get(Hc_PlotOver,'value') 
    ind=ind+1; 
    if ind == 8;ind=1;end 
    set(Ha_ax1,'NextPlot','Add'); 
    set(Ha_ax2,'NextPlot','Add'); 
    set(Ha_ax3,'NextPlot','Add');      
else 
    ind=1; 
    set(Ha_ax1,'NextPlot','Replace'); 
    set(Ha_ax2,'NextPlot','Replace'); 
    set(Ha_ax3,'NextPlot','Replace'); 
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end 
 
axes(Ha_ax1) 
plot(T,Qi,'b') 
hold on 
plot(T,Qo,'r') 
plot(T,Qa,'g') 
hold off 
title('FLOW') 
xlabel('flow') 
legend('Q_I_N','Q_O_U_T','Q_A_O_R_T_A') 
axes(Ha_ax2) 
plot(T,Pt) 
hold on 
plot(T,Ps,'r') 
plot(T,Pao,'r') 
plot(T,Pv,'g') 
%plot(T,Ea(1:length(Pv)),'g--') 
hold off 
title('PRESSURE') 
legend('Pt','Pao','Plv') 
if strcmp(simu,'novacor')|strcmp(simu,'thoratec') 
    hold on 
    plot(T(te),eject(te),'r.') 
    hold off 
end 
xlabel('Thoratec Chamber Pressure') 
 
axes(Ha_ax3) 
%plot(T,Pao,colors(ind)) 
plot(T,Vvad) 
hold on 
plot(T,Vlv,'r') 
plot(T,Pexternal,'g') 
legend('Vvad','Vlv','Pex') 
xlabel('Volume') 
hold on 
%hold off 
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% EofT.M     
% CODE IS USED TO CREATE THE TIME-VARYING ELASTANCE FUNCTION 
% E(T) 
 
function Ev=EofT(T,HR,Emax,step) 
 
%CREATE A MATRIX OF E(T) VALUES FOR THE LENGTH OF THE 
SIMULATION 
% T = SIMULATION TIME 
% HR = HEART RATE (BPM) 
% EMAX = MAXIMUM ELASTANCE OF THE LV 
% STEP = STEP SIZE OF SIMULATION 
 
 
En=[]; 
Tc=60/HR;                   %Find cycle time for one beat 
tmax = 0.2 + 0.1555*Tc;     %Find time of systole from cycle 
time 
points = Tc/step;           %Calculate number of samples in one 
cycle 
r = ceil(length(T)/points); %Find number of cycles needed, 
rounding to upper integer 
 
for j = 1:r+1 
    for i = 1:points 
        tn(i) = i*(step/tmax); 
        t1 = (tn(i)/0.7)^1.9; 
        t2 = 1 + t1; 
        t3 = 1 + (tn(i)/1.173474)^21.9; 
        Ecyc(i) = 1.553174*(t1/t2)*(1/t3); 
    end 
    En(length(En)+1:length(En)+points) = Ecyc; 
    %clear Ecyc 
end 
 
En=En(1:length(T)); 
 
%Plv = E(t)[Vlv-Vd] + m[Vlv-Vd]  Active + Passive 
% Passive Pressure has been simplified to a linear relationship 
% because the Ax+B method of solving does not allow non-linear 
% E(t) function to be used. 
 
% From simulation slope of EDPVR assuming linear 
m = .06; 
 
Ev=En*Emax; 
tsamp = tn*tmax; 
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%RUNKUT4.M   4TH ORDER RUNGE-KUTTA METHOD 
 
function x=runkut4(h,A,x,B,u) 
% RUNGE KUTTA 4TH ORDER METHOD FOR NUMERICAL  
% SOLUTION TO LINEAR FIRST ORDER DIFF EQ'S 
 
xdot = A*x+B*u; 
kx1  = h*xdot; 
x1   = x+0.5*kx1; 
 
xdot = A*x1+B*u; 
kx2  = h*xdot; 
x1   = x+0.5*kx2; 
 
xdot = A*x1+B*u; 
kx3  = h*xdot; 
x1   = x+kx3; 
 
xdot = A*x1+B*u; 
kx4  = h*xdot; 
 
x    = x+(kx1+2*kx2+2*kx3+kx4)/6; 
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% THORATEC_CARDIO_FINAL.M 
% FINDS A NUMERICAL SOLUTION FOR 8 STATE EQUATIONS FOR THE  
% THORATEC/CVS MODEL  
 
% Series Inductor Resistor Capacitor model with Di/Do in state 
equations for leaky valves. 
clear cycle_start cycle_end ej 
 
%IF THORATEC IS ON, USE LEAKY VALVES 
if get(Hc_PumpOn,'Value') 
    open = 1; 
    leakin  = 0.08 
    leakout = 0.03 
% IF THORATEC IS OFF, CLOSED VALVES = 0 
else 
    cycle_start = 1; 
    cycle_end   = 100; 
    open = 0; 
    leakin = 0; 
    leakout = 0; 
end 
 
%State equation dX/dt=A(t)*X(t)+B(t)*Vd; 
%Initialize the coefficient matrix 
A=zeros(8); 
%Initialize Variables 
Qi(1)=0; Qa(1)=0; Qo(1)=0; Qv(1) = 0; 
Pr(1)=5; Pa(1)=90;Pao(1)=Pa(1);  
Vr(1)=Cr*Pr(1); Vp(1)=Cs*Pa(1);Vao(1)=Cao*Pao(1); 
Vlv(1)=V_total-Vvad(1)-Vr(1)-Vp(1)-Vao(1);Vvad(1)=50;  
V_sum(1)=Vlv(1)+Vr(1)+Vp(1)+Vao(1)+Vvad(1); 
Pv(1)=(Vlv(1)-Vd)*(Ea(1)+Ep)-Ep*dV; 
 
%Initialize the x-matrix (state variables) 
x=zeros(8,1); 
x=[Qi(1) Qo(1) Vvad(1) Pao(1) Qa(1) Vlv(1) Pa(1) Pr(1) ]'; 
xdot=[0 0 0 0 0 0 0]; 
 
Vlv(1)=V_total-Vvad(1)-Vr(1)-Vp(1); 
j=1; 
j2=1; 
 
% Delay logic implemented so that valves stay open for 100 ms 
% to allow flow to get above zero.  Necessary for the current 
% valve modeling logic 
 
delay_in = -100; 
delay_out = -100; 
Ri0 = Ri; 
k=1; 
% Begin Simulations. n = number of iterations to be performed 
for i=1:n-1 
     
    % Optional code used if an occlusion run is desired 
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    %%%%%% Occlusion Run %%%%%% 
    % if i>(end_t*500) Rs = 0.83+((0.25*(i-
end_t*500))/1000);end 
    % Rsys(i) = Rs;     
    %determine the valve status  
     
    %VALVE LOGIC - FOR 2 LV VALVES, M = MITRAL, A = AORTIC 
    if Pr(i)>=Pv(i) 
        Dm=1; 
    else 
        Dm=0; 
    end 
     
    if Pv(i) >= Pao(i) 
        Da=1; 
    else 
        Da=0; 
    end 
 
    %THORATEC VALVE LOGIC - I = INLET, O = OUTLET 
     
    if Di == leakin         %IF VALVE IS CLOSE 
        if Pv(i) >= Pt(i)   % & IF ventricle presure > VAD 
pressure 
            Di=open;        % Open inlet valve 
            delay_in = i;   % Start delay, so flow can reach 
positive 
        end 
    else 
        if x(1) <= 0 & i > delay_in + 100 
            Di=leakin;      % Close valve if flow < 0, and 
delay is over 
        end 
    end 
     
    %Idendical Logic used for outlet valve 
    if Do == leakout 
        if Pt(i) >= Pao(i) 
            Do=open; 
            delay_out = i; 
        end 
    else 
        if x(2) <= 0 & i > delay_out + 100 
            Do=leakout;   
        end 
    end 
 
    % Determine the VAD drive pressure status (mode) and aplied 
value (Pd) 
    % Three Driver Controls Possible 
    ejectmode='fill2empty'; 
    bpm=70; 
    per_sys = t_eject/((1000*60)/bpm); 
    switch ejectmode 
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    % FILL-TO-EMPTY, Eject once VAD volume reaches Tmax_vol 
    % Duration of ejection = t_eject-n 
    case 'fill2empty' 
        if mode == 0 
            if x(3) >= Tmax_vol 
                if exist('cycle_end'); 
                    cycle_start = cycle_end; 
                end 
                cycle_end = i; 
                mode = 1; 
                ej(k) = i; 
                k=k+1; 
                Pd = Pte; 
                t_eject_nc = i+t_eject_n; 
            else 
                Pd = Ptf; 
            end 
        else 
            if i == t_eject_nc 
                mode = 0; 
                Pd = Ptf; 
            else 
                Pd = Pte; 
            end 
        end 
    %Fixed ejection rate, set by variable 'bpm'     
    case 'fixed' 
        if j >= (1000*60)/bpm; 
            if i+j < n 
                cycle_start=i; 
                cycle_end  =i+j; 
            end 
            j=1; 
            mode = 1; 
            Pd = Pte; 
        elseif j > per_sys*(1000*60)/bpm; 
            mode = 0; 
            Pd = Ptf; 
        end 
    % Pulse ejection rate, singe beat 
    case 'pulse' 
        if i < 2000 
            mode=0; 
            Pd=0; 
        elseif i >=2000 & i<4000 
            mode=0; 
            Pd=250; 
        elseif i >=4000 
            mode = 0; 
            Pd   = 0; 
        end 
    end 
    j=j+1; 
    % DETERMINE VALUE OF VAD BLADDER COMPLIANCE 
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    % BASED ON VAD VOLUME OF THE PREVIOUS ITERATION 
     
    if x(3)> 112 
        Cp = 1/44.40; 
        Vd_vad = 111.148;      
    elseif x(3) > 107 
        Cp = 1/7.57; 
        Vd_vad = 107;     
    elseif x(3) > 32 - 0 %- 21.4/cslope      
        Cp = 1/.20; 
        Vd_vad = 107; 
    elseif x(3) > 22-0    
        Cp = 1/4.07; 
        Vd_vad = 35.69-0;        
    else  
        Cp = 1/17.63; 
        Vd_vad = 25.16-0; 
    end 
     
    % Calulate the External Bladder Pressure from the Drive 
Pressure (Pd) 
    % Pexdot = (1/RC)Pdriver - (1/RC)Pex 
    A2 = [-1/(Rd*Cd)]; 
    B2 = -A2; 
    Pex=runkut4(step,A2,Pex,B2,[Pd]); 
    xdot2=A2*Pex+B2*[Pd]; 
    Pex2 = Pex+xdot(3)*.15; 
     
    Ri = Ri0 + exp(-.25*x(6));          % EXPRESSION FOR 
VENTRICLE COLLAPSE MODEL 
    Ro = 0.00015*abs(Qo(i)) + 0.05;     % EXPRESSION FOR FLOW 
DEPENDENT OUTLET RESISTOR 
 
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%  
     
    % SIMPLIFY STATE SPACE MODEL BY TAKING PARAMETERS INTO LESS 
COMPLEX FORM 
    xo  = (Do*Lp)/(Lp+Lo); 
    xi  = (Di*Lp)/(Lp+Li); 
    zi  =  Di/(Lp+Li); 
    zo  =  Do/(Lp+Lo); 
    ri  = (Di*Rp)/(Lp+Li); 
    ro  = (Do*Rp)/(Lp+Lo); 
    rri = (Do*Rp+Ri)/(Do*Lp+Li); 
    rro = (Di*Rp+Ro)/(Di*Lp+Lo); 
     
    % CREATE COEFFICIENT MATRIX A 
    %            Qi          Qo           Vvad           Pao    
Qa         Vlv               Pa       Pr 
    A(1,:)=[ xi*ro-rri     ri-xi*rro   (xi*zo-zi)/Cp   -xi*zo    
0     zi*(Ea(i)+Ep)          0        0         ]/(1-xi*xo); 
    A(2,:)=[ ro-xo*rri     xo*ri-rro   (zo-xo*zi)/Cp     -zo     
0    xo*zi*(Ea(i)+Ep)        0        0         ]/(1-xi*xo); 
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    A(3,:)=[      1          -1             0             0      
0          0                 0        0         ]; 
    A(4,:)=[      0           1             0          -Da/Ra   
-1   (Da/Ra)*(Ea(i)+Ep)       0        0         ]/Cao;  
    A(5,:)=[      0           0             0             1     
-Rc         0                -1        0         ]/Ls; 
    A(6,:)=[     -1           0             0           Da/Ra    
0 -[Dm/Rm+Da/Ra]*(Ea(i)+Ep)  0      Dm/Rm       ]; 
    A(7,:)=[      0           0             0             0      
1          0               -1/Rs    1/Rs        ]/Cs; 
    A(8,:)=[      0           0             0             0      
0   (Dm/Rm)*(Ea(i)+Ep)      1/Rs  -(1/Rs+Dm/Rm) ]/Cr; 
     
    %CREATE CONSTANT MATIX B 
    %[Vd_vad;Pex;Vd;Ep] 
    B(1:2,1) = -A(1:2,3); 
    B(1:2,2) =  A(1:2,3)*Cp; 
    B(1:8,3) = -A(1:8,6); 
    B(1:8,4) = -A(1:8,6)*(Ep*dV)/(Ea(i)+Ep); 
     
    %integration of dX/dt using Runge-Kutta 4th order 
intergration method; 
    x=runkut4(step,A,x,B,[Vd_vad;Pex2;Vd;1]); 
     
    %calculate current derivatives 
     
    xdot=A*x+B*[Vd_vad;Pex2;Vd;1]; 
     
    %store data in the simulation variables; 
    %v(i)=val; 
    Qi(i+1)   = x(1);                                      % 
Thoratec Inflow; 
    Qo(i+1)   = x(2);                                      % 
Thoratec Outflow; 
    Vvad(i+1) = x(3); 
    Pao(i+1)  = x(4); 
    Qa(i+1)   = x(5); 
    Vlv(i+1)  = x(6); 
    Pa(i+1)   = x(7); 
    Pr(i+1)   = x(8); 
     
    Pv(i+1) = (x(6)-Vd)*(Ea(i+1)+Ep)-Ep*dV; 
    Pp(i+1) = (x(3)-Vd_vad)/Cp;                           % 
Thoratec Pump Presure - due to bladder compliance only; 
    Px(i+1) = Pp(i+1)+Pex2;                               % 
Thoratec Bladder Chamber Pressure - total; 
    Pt(i+1) = Px(i)+Rp*(Qi(i)-Qo(i))+Lp*(xdot(1)-xdot(2)); 
    Qv(i+1) = Da*(Pv(i+1)-Pao(i+1))/Ra; 
    Pdrive(i+1) = Pex;                                    % 
Thoratec Pump Driver Pressure(mmHg); 
    Pexternal(i+1)=Pex2; 
    Vp(i+1) = Cs*x(7);                                    % 
Volume in peripheral systemic capacitor; 
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    Vr(i+1) = Cr*x(8);                                    % 
Volume in atrial capacitor; 
    Vao(i+1)= Cao*x(4); 
    V_sum(i+1) = x(6)+Vr(i+1)+Vp(i+1)+Vao(i+1)+x(3);  % Total 
CV volume 
    bladder_comp(i+1) = Cp; 
    if mode == 0 
        te(i)=0; 
    else 
        te(i)=i; 
    end 
    te=nonzeros(te)'; 
    %Qs(i+1)=Cs*xdot(4); 
     
    eject(i)   = mode; 
    Din(i)     = Di; 
    Dout(i)    = Do; 
    Daorta(i)  = Da; 
    Dmitral(i) = Dm; 
     
    Amat{i}=A; 
    Bmat{i}=B; 
    Qao(i) = xdot(4)*Cao; 
    Qv(i)  = Da*(Pv(i)-Pao(i))/Ra; 
    xx(:,i)=x; 
    xxdot(:,i)=xdot; 
    Aobalance(i) = Qo(i)+Da*(Pv(i)-Pao(i))/Ra - Qa(i) - 
Cao*xdot(4); 
end 
 
set(Hc_meanQ,'string',num2str(mean(Qo(cycle_start:cycle_end))))
; 
set(Hc_meanP,'string',num2str(mean(Pao(cycle_start:cycle_end)))
); 
 
%DETERMINE MEAN VALUES OF THE LAST COMPLETE BEAT RUN 
 
rate_n   = 60/[(cycle_end-cycle_start)*step]; 
max_Ps   = max(Pao(cycle_start:cycle_end)); 
mean_Ps  = mean(Pao(cycle_start:cycle_end)); 
min_Ps   = min(Pao(cycle_start:cycle_end)); 
 
max_Pv   = max(Pv(cycle_start:cycle_end)); 
mean_Pv  = mean(Pv(cycle_start:cycle_end)); 
min_Pv   = min(Pv(cycle_start:cycle_end)); 
 
max_Qo   = max(Qo(cycle_start:cycle_end)); 
mean_Qo  = mean(Qo(cycle_start:cycle_end)); 
min_Qo   = min(Qo(cycle_start:cycle_end)); 
max_Qi   = max(Qi(cycle_start:cycle_end)); 
mean_Qi  = mean(Qi(cycle_start:cycle_end)); 
min_Qi   = min(Qi(cycle_start:cycle_end)); 
max_Pt   = max(Pt(cycle_start:cycle_end)); 
mean_Pt  = mean(Pt(cycle_start:cycle_end)); 
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min_Pt   = min(Pt(cycle_start:cycle_end)); 
 
max_Pex   = max(Pexternal(cycle_start:cycle_end)); 
mean_Pex  = mean(Pexternal(cycle_start:cycle_end)); 
min_Pex   = min(Pexternal(cycle_start:cycle_end)); 
 
max_Vlv   = max(Vlv(cycle_start:cycle_end)); 
min_Vlv   = min(Vlv(cycle_start:cycle_end)); 
SVlv      = max_Vlv-min_Vlv; 
 
max_V   = max(Vvad(cycle_start:cycle_end)); 
min_V   = min(Vvad(cycle_start:cycle_end)); 
SV      = max_V-min_V; 
 
%DISPLAY MEAN VALUES 
disp('') 
disp('RESULTS') 
disp(' ') 
disp(sprintf('Cycle: %g,%g',[T(cycle_start) T(cycle_end)])) 
disp(sprintf('Rate:  %g',rate_n)) 
disp(' ') 
disp(sprintf('Max  Ps:  %g',max_Ps)) 
disp(sprintf('Mean Ps:  %g',mean_Ps)) 
disp(sprintf('Min  Ps:  %g',min_Ps)) 
disp(' ') 
disp(sprintf('Max  Pv:  %g',max_Pv)) 
disp(sprintf('Mean Pv:  %g',mean_Pv)) 
disp(sprintf('Min  Pv:  %g',min_Pv)) 
disp(' ') 
disp(sprintf('Max  Qo:  %g',max_Qo)) 
disp(sprintf('Mean Qo:  %g',mean_Qo)) 
disp(sprintf('Min  Qo:  %g',min_Qo)) 
disp(' ') 
disp(sprintf('Max  Qi:  %g',max_Qi)) 
disp(sprintf('Mean Qi:  %g',mean_Qi)) 
disp(sprintf('Min  Qi:  %g',min_Qi)) 
disp(' ') 
disp(sprintf('Max  Pt:  %g',max_Pt)) 
disp(sprintf('Mean Pt:  %g',mean_Pt)) 
disp(sprintf('Min  Pt:  %g',min_Pt)) 
disp(' ') 
disp(sprintf('Max  Pex:  %g',max_Pex)) 
disp(sprintf('Mean Pex:  %g',mean_Pex)) 
disp(sprintf('Min  Pex:  %g',min_Pex)) 
disp(' ') 
disp(sprintf('Max  Vlv:  %g',max_Vlv)) 
disp(sprintf('Min Vlv:  %g',min_Vlv)) 
disp(sprintf('Stroke Vlv:  %g',SVlv)) 
disp(' ') 
disp(sprintf('Max  Vol:  %g',max_V)) 
disp(sprintf('Min Vol:  %g',min_V)) 
disp(sprintf('Stroke Vol:  %g',SV)) 
disp(' ') 
disp(' ') 
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 % THORATEC3A.M 
% SOLVE THE DIFF EQ'S FOR THE IN-VITRO EXPERIMENTS 
%Ri and Ro 
%Cd value 
%leakin and leakout 
%PV curve moved lower half left 
% 
% 
% 
 
% Series Inductor Resistor Capacitor model with Di/Do in state 
equations for leaky valves. 
clear cycle_start cycle_end 
%State equation dX/dt=A(t)*X(t)+B(t)*Vd; 
simu='thoratec'; 
A=zeros(4); 
leakin  = 0.08 
leakout = 0.03 
x=zeros(7,1); 
x=[Qi(1) Qo(1) Vvad(1) Ps(1)]'; 
xdot=[0 0 0 0]; 
 
j=1; 
j2=1; 
delay_in = -100; 
delay_out = -100; 
 
for i=1:n-1     
    %determine the valve status  
    if Di == leakin  
        if Pi >= Pt(i) 
            Di=1; 
            delay_in = i; 
        end 
    else 
        if x(1) <= 0 & i > delay_in + 100 
            Di=leakin; 
        end 
    end 
     
    if Do == leakout 
        if Pt(i) >= Ps(i) 
            Do=1; 
            delay_out = i; 
        end 
    else 
        if x(2) <= 0 & i > delay_out + 100 
            Do=leakout;   
        end 
    end 
 
    % FILL TO EMPTY 
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    % Determine the VAD drive pressure status (mode) and aplied 
value (Pd) 
    ejectmode='fill2empty'; 
    bpm=60; 
    per_sys = t_eject/((1000*60)/bpm); 
    switch ejectmode 
    case 'fromfile' 
    case 'fill2empty' 
        if mode == 0 
            if x(3) >= Tmax_vol 
                if exist('cycle_end'); 
                    cycle_start = cycle_end; 
                end 
                cycle_end = i; 
                mode = 1; 
                Pd = Pte; 
                Rd=.01; 
                Cd=4; 
                t_eject_nc = i+t_eject_n; 
            else 
                Pd = Ptf; 
                Rd=.01; 
                Cd=4; 
            end 
        else 
            if i == t_eject_nc 
                mode = 0; 
                Pd = Ptf; 
                Rd=.01; 
                Cd=4; 
            else 
                Pd = Pte; 
                Rd=.01; 
                Cd=4; 
            end 
        end 
    case 'fixed' 
        if j >= (1000*60)/bpm; 
            if i+j < n 
                cycle_start=i; 
                cycle_end  =i+j; 
            end 
            j=1; 
            mode = 1; 
            Pd = Pte; 
            Rd=.01; 
            Cd=3; 
        elseif j > per_sys*(1000*60)/bpm; 
            mode = 0; 
            Pd = Ptf; 
            Rd=.01; 
            Cd=1; 
        end 
    case 'pulse' 
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        if i < 2000 
            mode=0; 
            Pd=0; 
        elseif i >=2000 & i<4000 
            mode=0; 
            Pd=250; 
        elseif i >=4000 
            mode = 0; 
            Pd   = 0; 
        end 
    end 
    j=j+1; 
    nx=0; 
     if x(3)> 112-2 
         Cp = 1/44.40; 
         Vd_vad = 111.148-2;      
     elseif x(3) > 107-2 
         Cp = 1/7.57; 
         Vd_vad = 107-2;     
     elseif x(3) > 32 
         Cp = 1/.20; 
         Vd_vad = 107-2; 
     elseif x(3) > 22       
         Cp = 1/4.07; 
         Vd_vad = 35.69; 
          
     else  
         Cp = 1/17.63; 
         Vd_vad = 25.16; 
      end 
 
    % Calulate the External Bladder Pressure from the Drive 
Pressure (Pd) 
    % Pexdot = (1/RC)Pdriver - (1/RC)Pex 
    A2 = [-1/(Rd*Cd)]; 
    B2 = -A2; 
    Pex=runkut4(step,A2,Pex,B2,[Pd]); 
    xdot2=A2*Pex+B2*[Pd]; 
    Pex2 = Pex+xdot(3)*.15; 
    
    Ro = 0.00015*abs(Qo(i)) + 0.05; 
    %   Ri = 0.00025*abs(Qi(i)) + 0.06; 
    %   else 
    %   Ri = [2*Qi(i)^2 + 200*Qi(i) + 37100]/1000000; 
    %   Ro = [2*Qo(i)^2 + 200*Qo(i) + 37100]/1000000; 
    % Rout(i) = Ro; 
    % Rin(i) = Ri; 
    %   end 
    %   Rout(i)=Ro; 
    %   Rp = abs([6e-7*(Qi(i)-Qo(i)).^2 + 1e-5*(Qi(i)-Qo(i)) + 
0.005]); 
    %   Rpump(i) = Rp;  
    %   Lp = Lpf*(100/Vvad(i)); 
    %   Pex=Pd(j2); 
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    %   j2=j2+1; 
    %   if j2 > length(Pd);j2=1;end 
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%  
     
    xo=(Do*Lp)/(Lp+Lo); 
    xi=(Di*Lp)/(Lp+Li); 
    zi=Di/(Lp+Li); 
    zo=Do/(Lp+Lo); 
    ri = (Di*Rp)/(Lp+Li); 
    ro = (Do*Rp)/(Lp+Lo); 
    rri = (Do*Rp+Ri)/(Do*Lp+Li); 
    rro = (Di*Rp+Ro)/(Di*Lp+Lo); 
     
     
    A(1,:)=[[xi*ro-rri] [ri-xi*rro] (xi*zo-zi)/Cp -xi*zo]/(1-
xi*xo); 
    A(2,:)=[ro-xo*rri xo*ri-rro (zo-xo*zi)/Cp -zo]/(1-xi*xo); 
    A(3,:)=[1 -1 0 0]; 
    A(4,:)=[0 1 0 -1/Rs]/Cs;  
     
    %[Vd_vad;Pex;Pi;Pe] 
    B(1:4,1) = -A(1:4,3); 
    B(1,2) = A(1,3)*Cp; 
    B(1,3) = zi; 
    B(2,2) = A(2,3)*Cp; 
    B(2,3) = xo*zi; 
    B(4,4) = 1/(Cs*Rs); 
     
     
    %integration of dX/dt using Runge-Kutta 4th order 
intergration method; 
    x=runkut4(step,A,x,B,[Vd_vad;Pex2;Pi;Pe]); 
     
    eject(i) = mode; 
    Din(i) = Di; 
    Dout(i) = Do; 
     
     
    %calculate current derivatives 
    xdot=A*x+B*[Vd_vad;Pex2;Pi;Pe]; 
     
    %store data in the simulation variables; 
    %v(i)=val; 
    Qi(i+1) = x(1);                                      % 
Thoratec Inflow; 
    Qo(i+1) = x(2);                                      % 
Thoratec Outflow; 
    Vvad(i+1) = x(3);                                    % 
Volume in VAD 
    Pp(i+1) = (x(3)-Vd_vad)/Cp;                          % 
Thoratec Pump Presure - due to bladder compliance only; 
    Ps(i+1) = x(4);                                      % 
Systemic Pressure 
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    Px(i+1) = Pp(i+1)+Pex2;                               % 
Thoratec Bladder Chamber Pressure - total; 
    Pt(i+1) = Px(i)+Rp*(Qi(i)-Qo(i))+Lp*(xdot(1)-xdot(2)); 
    dQidt(i)= xdot(1); 
    dQodt(i)= xdot(2); 
    %Pdrive(i+1) = Pd;                                   % 
Thoratec Pump Driver Pressure(mmHg); 
    Pexternal(i+1)=Pex2; 
     
    Vs(i+1) = Cs*x(4); 
    V_sum(i+1) =Cs*Ps(i+1)+x(3);                         % 
Total CV volume    
    bladder_comp(i+1) = Cp; 
    if mode == 0 
        te(i)=0; 
    else 
        te(i)=i; 
    end 
    te=nonzeros(te)'; 
    Qs(i+1)=Cs*xdot(4); 
    Qv(i+1)=xdot(3); 
    Qe(i+1)=(Ps(i)-Pe)/Rs; 
    Amat{i}=A; 
    Bmat{i}=B; 
    %Pex_new(i)=Pex+xdot(3)*.1; 
end 
 
set(Hc_meanQ,'string',num2str(mean(Qo(cycle_start:cycle_end))))
; 
set(Hc_meanP,'string',num2str(mean(Ps(cycle_start:cycle_end))))
; 
 
rate_n   = 60/[(cycle_end-cycle_start)*step]; 
max_Ps   = max(Ps(cycle_start:cycle_end)); 
mean_Ps  = mean(Ps(cycle_start:cycle_end)); 
min_Ps   = min(Ps(cycle_start:cycle_end)); 
 
max_Qo   = max(Qo(cycle_start:cycle_end)); 
mean_Qo  = mean(Qo(cycle_start:cycle_end)); 
min_Qo   = min(Qo(cycle_start:cycle_end)); 
 
max_Qi   = max(Qi(cycle_start:cycle_end)); 
mean_Qi  = mean(Qi(cycle_start:cycle_end)); 
min_Qi   = min(Qi(cycle_start:cycle_end)); 
 
max_Pt   = max(Pt(cycle_start:cycle_end)); 
mean_Pt  = mean(Pt(cycle_start:cycle_end)); 
min_Pt   = min(Pt(cycle_start:cycle_end)); 
 
max_Pp   = max(Pp(cycle_start:cycle_end)); 
mean_Pp  = mean(Pp(cycle_start:cycle_end)); 
min_Pp   = min(Pp(cycle_start:cycle_end)); 
 
max_Pex   = max(Pexternal(cycle_start:cycle_end)); 
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mean_Pex  = mean(Pexternal(cycle_start:cycle_end)); 
min_Pex   = min(Pexternal(cycle_start:cycle_end)); 
 
max_V   = max(Vvad(cycle_start:cycle_end)); 
min_V   = min(Vvad(cycle_start:cycle_end)); 
SV      = max_V-min_V; 
 
disp('') 
disp('RESULTS') 
disp(' ') 
disp(sprintf('Cycle: %g,%g',[T(cycle_start) T(cycle_end)])) 
disp(sprintf('Rate:  %g',rate_n)) 
disp(' ') 
disp(sprintf('Max  Ps:  %g',max_Ps)) 
disp(sprintf('Mean Ps:  %g',mean_Ps)) 
disp(sprintf('Min  Ps:  %g',min_Ps)) 
disp(' ') 
disp(sprintf('Max  Qo:  %g',max_Qo)) 
disp(sprintf('Mean Qo:  %g',mean_Qo)) 
disp(sprintf('Min  Qo:  %g',min_Qo)) 
disp(' ') 
disp(sprintf('Max  Qi:  %g',max_Qi)) 
disp(sprintf('Mean Qi:  %g',mean_Qi)) 
disp(sprintf('Min  Qi:  %g',min_Qi)) 
disp(' ') 
disp(sprintf('Max  Pt:  %g',max_Pt)) 
disp(sprintf('Mean Pt:  %g',mean_Pt)) 
disp(sprintf('Min  Pt:  %g',min_Pt)) 
disp(' ') 
disp(sprintf('Max  Pp:  %g',max_Pp)) 
disp(sprintf('Mean Pp:  %g',mean_Pp)) 
disp(sprintf('Min  Pp:  %g',min_Pp)) 
disp(' ') 
disp(sprintf('Max  Pex:  %g',max_Pex)) 
disp(sprintf('Mean Pex:  %g',mean_Pex)) 
disp(sprintf('Min  Pex:  %g',min_Pex)) 
disp(' ') 
disp(sprintf('Max  Vol:  %g',max_V)) 
disp(sprintf('Min Vol:  %g',min_V)) 
disp(sprintf('Stroke Vol:  %g',SV)) 
disp(' ') 
disp(' ') 
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DIFFERENTIAL EQUATIONS 
 
 
 
Thoratec Model – CVS 
 
 
Figure 49: VAD-CVS electric analog diagram 
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Table 6: Definition of Parameters 
Po pressure prescribed by the Thoratec driver  
Pd pressure developed in the Thoratec driver 
Pex pressure exerted on the Thoratec bladder 
PT  pressure in the Thoratec bladder (pneumatic + passive) 
PP  passive pressure created in the Thoratec bladder  
Ri  resistance of the Thoratec inlet valve (dependent on VLV) 
Ro  resistance of the Thoratec outlet valve (dependent on QO) 
Li  inertance of the Thoratec inlet cannula 
LP  inertance of the Thoratec chamber volume 
Lo  inertance of the Thoratec outlet cannula 
RA resistance of the aortic valve; includes R’c 
RC characteristic resistance of the systemic system 
RP  resistance of the Thoratec chamber 
RD  resistance of the Thoratec drive line (air) 
CP  compliance of the Thoratec bladder 
CAo compliance of the aorta 
Cs compliance of the systemic system 
CR compliance of the atria 
CD  compliance of the Thoratec drive line (air) 
Qi  Thoratec inlet flow 
Qo  Thoratec outlet flow 
Di  Thoratec inlet valve  
Do  Thoratec outlet valve 
 
Table 7: System State Variables 
Vlv Volume of Left Ventricle 
QA Flow in the Aorta 
PA Arterial Pressure 
Pr Atrial Pressure 
Qi Thoratec Inlet Flow 
Qo Thoratec Outlet Flow 
VV Volume of the VAD 
 
Beginning with the Thoratec driver, to find the external drive pressure on the pump chamber 
 
d o
D D D D
1 1P = P - P
C R C R
  
?
d        (A-1) 
 
The pressure source Po is a square wave generated by the Thoratec driver.  Po is initially a filling 
pressure near or below 0.0 mmHg.  Once the volume of the VAD reaches a volume of 104 ml, Po 
steps to an ejection pressure, usually between 200-250 mmHg.  The ejection pressure will remain 
constant for a period of time equal to the VAD ejection time, set by the user.  Po will then return 
at its filling pressure until the volume of the VAD again reaches 104 ml. 
The actual pressure exerted on the VAD bladder (PEX) is given by the following relationship: 
 
ex VP =αV?         (A-2) 
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The total pressure in the Thoratec chamber is the sum of the external pressure (PEX) and the 
pressure due to the pump chamber compliance (PP).  PP is found from the pressure-volume 
relationship found from fitting experimental data.  The pressure-volume relationship used in this 
model is: 
  [P V D-VAD
V
1P = V -V
C(V )
]       (A-3) 
 
where VV, the VAD volume, is a state variable and VD-VAD is dead or relaxed the VAD. 
 
The Pressure in the left ventricle is found by summing the active pressure resulting from 
myocardial activation and the passive pressure resulting from ventricle filling.  The expression 
for active pressure is: 
 
[ ]Act A LV DP =E (t) V -V        (A-4) 
  
Where EA is the active elastance, found from the normalized curve, and VD is the unstressed 
volume or x-intercept of the ESPVR.  Passive pressure can be found by estimating the EDPVR 
by a linear relationship.  
 
[ ]pas P LV OP =E (t) V -V        (A-5) 
 
Adding the PAct and PPas yields: 
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[ ]LV LV O pP =E(t) V -V -E (t)*∆V      (A-6) 
 
where E(t) = EA(t) + Ep(t) and DO VVV −=∆ . 
Solving for the state variable, VLV: 
 
[ ] [M ALV R LV i LV Ao
M A
D DV = P -P -Q - P -P
R R
? ]        
 
M A M
LV R i LV Ao
M A M
D D D DV = P -Q - + P + P
R R R R
   
? A
A
      
 
PLV is not a state variable, and must be substituted for VLV. 
 
[ ]M A MLV R i LV D Ao
M A M
D D D DV = P -Q - + E(t) V -V + P
R R R R
   
? A
A
  (A-7) 
 
Similar calculations can be done on the capacitor nodes CS, CAo, and CR.   
 
A R
s A A
S
[P -P ]C P =Q -
R
?          
 
A A A
s s S s S
1 1 1P = Q - P + P
C C R C R
?
R      (A-8) 
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A LV Ao
Ao Ao o A
A
D [P -P ]C P = +Q -Q
R
?        
 
A A
Ao LV Ao o A
Ao A Ao A Ao Ao
D D 1 1P = P - P + Q - Q
C R C R C C
?      
 
[ ]A AAo LV D Ao o A
Ao A Ao A Ao Ao
D D 1 1P = E(t) V -V - P + Q - Q
C R C R C C
?    (A-9) 
 
[ ] [ ]R LV A R
R R M
M S
P -P P -P
C P =D +
R R
?        
 
[ ]M MR A LV D
R S R M R M R S
D D1 1P = P - E(t) V -V + - P
C R C R C R C R R
   
?   (A-10) 
 
Because Qi and Qo are both state variables, the change of volume of the VAD bladder is simply: 
 
V iV =Q -Q? o         (A-11) 
 
The change in flow across the inductor LS is easily defined with state variables. 
 
Ao A S A C AP -P =L Q +R Q?          
C
A Ao A
S S S
R1Q = P - Q +- P
L L L
?
A
1
      (A-12) 
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 The flow across the inlet (Qi) and outlet (Qo) inductors becomes more complex because the node 
PT is not a state variable.  The following expressions relate inlet and outlet flow intermediate 
variables: 
i i i LV i T i iL Q =D P -D P -R Q?         
 
o O o T o Ao o oL Q =D P -D P -R Q?         
The variable PT in terms of state variables, and derivatives of state variables is:  
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PT P ex i o P i oP =P +P +(Q -Q )R +(Q -Q )L? ?      (A-13) 
 
Substituting Equation A-13 into the expression for  above yield the following expression:  OQ?
 
 i     i i i LV i P ex i o P i o P iL Q =D P -D P +P +(Q -Q )R +(Q -Q )L -R Q? ? ?
 
The following algebraic steps were performed to solve in terms of the derivate of Qi and to 
remove  from the equation. oQ?
 
i i i P i LV i P i ex i P i i i P o i P oQ (L +D L )=D P -D P -D P -(D R +R )Q +D R Q +D L Q? ?    
 
i LV i P i ex i P i i i P o i P o
i
i i P
D P -D P -D P -(D R +R )Q +D R Q +D L QQ =
L +D L
??     
 i
o P i P
P o P i
oi i P i
LV P V d
P i P i P o P i
o o Pi P i P
Ao i
P o P i P i P o o P i
i
Q =
D L D L1-
L +L L +L
DD D L DP + - (P +αV P )
L +L L +L L +L L +L
D D RD L D L- P + -
L +L L +L L +L L +L D L +L
D L-
      
                
                      
?
?
o P iD R +R Q
i P oP i P
o
P i i P o P i
D R +R D R- Q
L +L D L +L L +L
                
 (A-14) 
 
The same steps to find Qi where implemented to solve for Qo. 
 
o O o P ex i o P i o P o Ao o oL Q =D P +P +(Q -Q )R +(Q -Q )L -D P -R Q? ? ?      
 
o o o P o P o ex o P i o P o o o P i o AoQ (L +D L )=D P +D P +D R Q -(D R +R )Q +D L Q -D P? ?   
 
o P o ex o P i o P o o o P i o Ao
o
o o P
D P +D P +D R Q -(D R +R )Q +D L Q -D PQ =
L +D L
??     
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oo P i P
P o P i
o P o o Pi i
LV P V d
P o P i P o P o P i
o o P o P o P i
Ao i
P o P o P o o P i
o
Q =
D L D L1-
L +L L +L
D L D D LD DP + - (P +αV P )
L +L L +L L +L L +L L +L
D D R D L D R +R- P + - Q
L +L L +L L +L D L +L
D L+
      
                      
                
?
?
P i P oi P
o
P o P i i P o
D R +RD R - Q
L +L L +L D L +L
                
  (A-15) 
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APPENDIX C 
 
 
 
 
THORATEC INLET VALVE RESISTOR CHARACTERIZATION 
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APPENDIX D 
 
 
 
 
MOCK CIRCULATORY SYSTEM RESISTOR CHARACTERIZATION 
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Figure 50: Pressure-flow characterization of Deltol needle valve (Deltol Fluid Products, Bellwood, Ill.)  Data 
series labels represent number of turns the handle is from the closed position.  
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